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ABSTRACT 
The oral cavity of healthy subjects is colonized by several and different microorganisms, such 
as viruses, bacteria, fungi and protozoa. Many of these are commensal species, which are 
essential to maintain a health status when in equilibrium with the environment, but can 
became pathogenic and capable to eliciting disease when occur environmental changes or 
shifts in the composition of the oral microbiota. Despite there are numerous studies 
concerning the bacterial communities inhabiting the oral cavity, there are very few studies 
defining the oral viral community and their role, if any, in the development of oral diseases. 
To date, the Human herpesviruses (HHVs) have been often associated with the development 
of periodontitis, while the Human Papillomaviruses (HPVs) have been studied as possible risk 
factor for the development of oropharyngeal cancer. Additionally, the Human Polyomaviruses 
(HPyVs) seems to be an excellent candidates as possible factors involved in the pathogenesis 
of oral diseases.  
Given the increasing incidence of oral diseases and the very limited study of viral 
involvement in these disorders, our study was aimed to give new insights on the possible 
presence of HPyVs and HPVs genomes in the oral mucosa of both 105 healthy subjects, 
without or with periodontitis (9) and 20 HIV positive patients. Nucleic acids isolation from 
saliva, buccal swab and paper points and subsequent Real Time PCR were the employed 
techniques.  
We could observe that the prevalence of HPyVs was significantly higher in the group of HIV 
positive subjects (60.0%) compared to the control group (25.7%), and among the HPyVs, the 
most prevalent were MCPyV: MCPyV genome was detected at the highest percentage 
(20.8%) and with high viral load (mean: 3.15*E+07) in all types of the oral specimens. 
Regarding the presence of HPVs, three high risk-HPV genotypes were detected in 2/20 
(10.0%) HIV positive subjects, only in the saliva samples.  
To our knowledge, this is the first study to examine and compare the presence of HPyVs and 
HPVs in a broad range of oral sample types. Based on our results, we could conclude that 
MCPyV may be part of the normal viroma of the oral cavity. Nonetheless, its well-known 
association with the Merkel Cell carcinoma leads to state the its presence should be 
monitored, in order to verify whether an association between MCPyV and oral diseases can be 
rule out. 
RIASSUNTO 
Il cavo orale dei soggetti sani è colonizzato da numerosi e differenti microorganismi, quali virus, 
batteri, funghi e protozoi. Molti di questi sono specie commensali, che essendo in equilibrio con il 
microambiente circostante sono essenziali per mantenere uno stato di salute, ma possono diventare 
patogene e capaci di causare malattie quando si verificano cambiamenti nel microambiente o nella 
composizione del microbioma orale. Sebbene vi siano numerosi studi riguardanti le comunità 
batteriche che abitano la cavità orale, pochissimi sono gli studi che definiscono la comunità virale 
orale e il suo ruolo, se esiste, nello sviluppo di patologie orali. Ad oggi, gli Herpesvirus umani 
(HHV) sono stati spesso associati allo sviluppo della parodontite, mentre i Papillomavirus umani 
(HPV) sono stati valutati come possibili fattori di rischio per lo sviluppo dei tumori orofaringei. In 
aggiunta, i Polyomavirus umani (HPyV) sono stati recentemente considerati candidati eccellenti 
come possibili fattori coinvolti nella patogenesi delle malattie orali.  
Data la crescente incidenza delle malattie orali e lo studio molto limitato riguardo al coinvolgimento 
virale in esse, il presente studio è stato volto a fornire nuove informazioni sulla presenza di HPyV e 
HPV nella mucosa orale di 105 soggetti sani, senza o con parodontite (9 soggetti) e 20 pazienti HIV 
positivi. Le tecniche impiegate sono state l’isolamento degli acidi nucleici da saliva, tampone 
buccale e paper points e successiva analisi tramite Real Time PCR.  
I risultati ottenuti mostrano che la prevalenza dei HPyV è risultata significativamente più alta nel 
gruppo di soggetti HIV positivi (60,0%) rispetto al gruppo di controllo (25,7%), e tra gli HPyV, il 
prevalente è stato MCPyV: il genoma di MCPyV è stato rilevato con la più alta percentuale (20,8%) 
e con la più alta carica virale (media: 3,15*E+07) in tutti i tipi di campioni orali. Per quanto 
riguarda la presenza di HPV, sono stati rilevati tre genotipi ad alto rischio in 2/20 soggetti HIV 
positivi (10,0%), solo nei campioni di saliva. A nostra conoscenza, questo è il primo studio 
condotto per valutare e confrontare la presenza di HPyV e HPV in un'ampia gamma di differenti 
campioni orali. Sulla base dei nostri risultati, potremmo concludere che MCPyV potrebbe far parte 
del normale viroma della cavità orale. Tuttavia, la sua ben nota associazione con il carcinoma a 
cellule di Merkel porta a suggerire che la sua presenza deve essere monitorata, al fine di verificare 
se è possibile escludere un'associazione tra MCPyV e patologie orali. 
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1.1 MICROBIOMA OF ORAL CAVITY  
Each human body contains a personalized microbiome, consisting of a complex community 
of foreign inhabitants, essential to maintain heath, but capable of eliciting disease (Zarco et 
al., 2012; Parahitiyawa et al., 2010). The human microbiome can be divided into: core 
microbiome and variable microbiome (Turnbaugh et al., 2007). The core microbiome is 
common to all individuals and consists of the predominant species, which are present in 
health conditions in different body districts (Turnbaugh et al., 2007; Zaura et al; 2009; 
Sonnenburg et al., 2011). However, there are several differences in species and strains 
(Dethlefsen et al.; 2007). The variable microbiome is characteristic of the single person and 
comes in response to unique lifestyle, phenotypic and genotypic elements (Figure 1). 
 
Figure 1. Human microbiome consists of a core microbiome, common to all individuals, and a variable 
microbiome, unique to individuals depending on lifestyle and physiological differences (Turnbaugh et al, 
2007). 
Each person harbors a unique microbiome that plays an important role in the etiology of some 
diseases, which can then manifest and progress differently between different individuals 
(Sonnenburg et al., 2011). It is therefore necessary to deepen the effect that these 
microorganisms have on the health of the host and to characterize the microbiome patterns 
involved in the diseases. This would allow faster diagnosis and establish personalized 
therapeutic strategies.  
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The oral cavity of healthy persons is strongly colonized by microorganisms, including viruses, 
bacteria, fungi, and protozoa. Many of these are responsible for the formation of biolfilms, 
which are resistant to mechanical stress and antibiotic treatments; many others are commensal 
species, which maintains health when in equilibrium. They can become pathogenic in 
response to certain ecological shifts in the microbiome, such as poor oral hygiene, 
immunological disorders and specific genetic compositions (Avila et al., 2015) (Figure 2).  
 
Figure 2. Cycle of ecological shifts in the oral microbiome that cause disease (Turnbaugh et al, 2007).  
The normal microbiota of the mouth is responsible for the two most common oral diseases of 
man: dental caries and periodontal diseases.  
The oral-pharyngeal cavity is composed of sophisticated anatomical structures. Various 
microorganisms colonize the environment provided by those structures, therefore a mucosal 
membrane and inherent mucosal immune system are indispensable for the protection of the 
integrity of the internal environment (Wu et al., 2014). Dysregulation of these innate and 
adaptive immune systems may play an important role in the etiology of infections, which are 
the basis of the periodontal disease, a highly prevalent complex infectious disease with 
several etiologic and contributory factors, resulting from inflammation of the supporting 
structures of the teeth (Ebersole et al., 2017; Slots 2017). Periodontitis affects the majority of 
adult subjects worldwide, but relatively few patients receive adequate treatment for the 
disease. Current periodontal therapy is successful in fighting initial and moderate types of 
periodontitis, but may show limited efficacy in resolving late-stage disease (Albandar et al., 
2005). A greater understanding of the etiopathogenetic process of periodontal disease seems 
to be a prerequisite for the development of preventive and therapeutic strategies, that are more 
efficient and less burdensome for patients.  
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Microbiological culture-dependent and culture-independent molecular studies have identified 
more than 1,200 bacterial species and 19,000 phylotypes in the oral cavity. At least 400 
bacterial species inhabit subgengival sites, but despite the long list of different bacteria in 
periodontitis, fewer than 20 species are considered to be major periodontal pathogens (Paster 
et al., 2006). Till now, there have been numerous studies about bacterial communities 
inhabiting the oral cavity, but fewer studies of the viral communities. Different types of 
viruses are frequent inhabitants of periodontitis lesions, but their role, if any, in the 
pathogenesis of the disease is still unknown. Research during the past 15 years has implied 
that Human Herpesviruses (HHV) are involved in the etiopathogenesis of destructive 
periodontal disease. It appears that a high periodontal load of active Epstein–Barr virus (EBV) 
and/or Human Cytomegalovirus (HCMV) is statistically associated with aggressive 
periodontitis, and latent HHVs infections are preferentially found in chronic periodontitis and 
gingivitis sites. Co-infection with EBV and HCMV shows a particularly close link with 
progressive periodontitis (Jakovljevic et al., 2014). Also, specific genotypes of herpesvirus 
species may exhibit increased periodontopathic potential. Because of the high copy-counts of 
EBV and HCMV in aggressive periodontitis, it is unlikely that these pathogenic viruses are 
acting merely as innocuous bystanders present in proportion to the severity of the underlying 
periodontal pathogenesis. Probably due to the difficulties of detection, the differences in 
sampling and the samples used, the studies on the presence of viruses in the oral cavity have a 
great variability. The studies on the healthy periodontium have showed few herpesvirus 
genomes, with a median genome detection rate of 8% for both EBV and HCMV. However, 
among the different studies there is a wide variation in the virus detection frequencies, that 
oscillate from 0% to 20% for Herpes Simplex Virus (HSV), from 0% to 23 % for EBV and 
from 0% to 57% for HCMV (Slots et al., 2010) (Table 1). 
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Table 1. Prevalence of Human Herpesviruses (HHVs) in periodontal health and gengivitis (Slots et al., 
2010) 
Virus 
Healthy periodontium 
% positive sample 
Gengivitis 
% positive sample 
Reference 
Herpes simplex 1  
(HSV) 
0% 0% Granier et al., 2009 
20% 53% Imbronito et al., 2008 
0% - Nishisyama et al., 2008 
0% - Sayagun et al., 2004 
0% - Contreas et al., 2000 
Epstein-Barr Virus 
(EBV) 
9% - Dawson et al., 2009 
23% 0% Grenier et al., 2009 
0% 20% Imbronito et al., 2008 
7% - Chalabi et al., 2008 
8% - Rotola et al., 2008 
- 13% Sayagun et al., 2008 
7% - Sunde et al., 2008 
3% - Moghim et al., 2007 
21% 20% Wu et al., 2008 
- 30% Watanabe et al., 2007 
0% - Klemenc et al., 2005 
9% - Konstantinidis et al.,2005 
6% - Sayagun et al., 2004 
18% - Contreas et al., 2000 
MEDIAN  8% 20%  
    
Human  
Cytomegalovirus  
(HCMV) 
0% - Dawson et al., 2009 
8% 25% Grenier et al., 2009 
57% 40% Imbronito 2008 
0% - Combs et al., 2008 
0% - Chalabi et al., 2008 
8% - Rotola et al., 2008 
13% - Ding et al., 2008 
0% - Sunde et al., 2008 
42% 49% Wu et al., 2008 
18% - Botero et al.,2007 
0% - Klemenc et al., 2005 
3% - Tantivanich et al., 2004 
32% - Chen et al., 2006 
0% - Sayagun et al., 2004 
9% - Contreas et al., 2000 
MEDIAN  8% 33% Sayagun et al., 2008 
 
Even among numerous studies on aggressive/chronic periodontitis, there is a considerable 
variability regarding the presence of HHVs. The prevalence of HSVs ranges from 13 to 100% 
with a total value of 52%, from 3 to 89% with an overall value of 52% for EBV, and finally 
from 0.3 to 89% with an overall value of 47% for HCMV (Slots et al., 2010) (Table 2).  
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Table 2. Prevalence of Human Herpesviruses (HHVs) in aggressive and chronic periodontitis (Slots et al., 
2010) 
Virus 
Aggressive Periodontitis 
% positive sample 
Chronic Periodontitis 
% positive sample 
Reference 
Herpes simplex 1  
(HSV) 
- 13% Granier et al., 2009 
57% 100% Bilichodmath et al., 2009 
87% 40% Imbronito et al., 2008 
- 16% Grande et al., 2008 
- 26% Nishiyama et al., 2008 
- 31% Ling et al., 2004 
78% - Sayagun et al., 2004 
- 21% Contreas et al., 2000 
MEDIAN 78% 26%  
    
Epstein-Barr Virus 
(EBV) 
- 28% Dawson et al., 2009 
- 3% Grenier et al., 2009 
29% 79% Bilichodmath et al., 2009 
33% 47% Imbronito et al., 2008 
- 48% Grande et al., 2008 
- 79% Chalabi et al., 2008 
55% 46% Rotola et al., 2008 
60% - Sayagun et al., 2004 
- 40% Sunde et al., 2008 
- 45% Imbronito et al., 2008 
- 61% Moghim et al., 2007 
- 38% Wu et al., 2008 
57% - Klemenc et al., 2005 
- 55% Konstantinidis et al.,2005 
89% 46% Kubar et al.,2005 
58% 23% Li et al., 2004 
- 4% Ling et al., 2004 
72% - Sayagun et al., 2004 
- 81% Contreas et al., 2000 
MEDIAN  58% 46%  
    
Human  
Cytomegalovirus  
(HCMV) 
- 0.3% Dawson et al., 2009 
- 35% Grenier et al., 2009 
7% 26% Bilichodmath et al., 2009 
47% 50% Imbronito et al., 2008 
- 59% Chalabi et al., 2008 
- 80% Grande et al., 2008 
44% - Ding et al., 2008 
- 80% Botero et al., 2007 
53% - Sayagun et al., 2004 
- 12% Sunde et al., 2008 
- 83% Imbronito et al., 2008 
- 63% Wu et al., 2008 
40% 60% Botero et al., 2007 
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7% - Wayanabe et al., 2007 
- 59% Chen et al., 2006 
- 3% Klemenc et al., 2005 
78% 27% Kubar et al.,2005 
- 34% Tantivanich et al., 2004 
- 52% Ling et al., 2004 
72% - Sayagun et al., 2004 
- 64% Contreas et al., 2000 
MEDIAN  42% 52%  
 
Furthermore, oral diseases associated with Human Immunodeficiency Virus (HIV) / Acquired 
Immune Deficiency Syndrome (AIDS) status includes mucosal diseases and destructive 
periodontal conditions (Ryder et al., 2012). Oral mucosal infections, especially candidiasis, 
are features of HIV disease, suggesting that compromised mucosal immunity within the oral 
cavity is a consequence of the viral infection. Despite HIV oral disease prevention has been 
partially advanced by improving patients access to highly active antiretroviral therapy 
(HAART), further preventive strategies are needed for minimizing the occurrence or 
recurrence of specific oral conditions (Patton et al., 2013). However, how this mucosal 
immunity is compromised is still unclear. Investigators have then realized that to fully 
understand human health and disease, we need to understand not just the few suspected 
pathogens, but rather all the microbial members of the oral environment. Moreover, the 
increased accessibility of sequencing technology and the improvement of the analytical 
capabilities can provide a newly approach to investigate in greater detail the oral microbial 
communities (Zhou et al., 2013). In immunocompromised patients, such as HIV-infected 
subjects, HSV, EBV and HCMV are found more frequently in the saliva samples and have 
been related to periodontitis and oral cancer (Fons, et al., 1994; Grande et al., 2008; Slots et 
al., 2009). The most commonly HHV identified in HIV-positive patients was HCMV, that 
was found in 81% periodontitis lesion, while EBV was detected in 57% of periodontitis 
biopsies (Contreas et al., 2001). However, HHV are probably not stand-alone 
periodontopathic agents, but cooperate with specific bacteria in periodontal tissue breakdown. 
A co-infection of active herpesviruses and periodontopathic bacteria may constitute a major 
cause of periodontitis and explain a number of the clinical characteristics of the disease 
(Saygun et al., 2004).  
Additionally, another family of viruses, called Human Papillomaviruses (HPV), that are 
strictly related to different oropharyngeal cancers, could be implicated in periodontal 
disorders. This viral family consist of a group of epitheliotropic viruses associated with cell 
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proliferative processes and may be benign (warts and condylomas) and pre-malign or malign 
(leukoplakia and carcinomas) in the stratified epithelia of the skin and mucosa. (Sanders et al., 
2015). The prevalence of HPV in the oral cavity has not yet been studied in a deep way as it 
for the vaginal tract. While the prevalence of these viruses in oropharyngeal cancers has 
increased, with estimates of 72% in America and in Europe (Mehanna, et al., 2013), 
prevalence of their oral infection in heathy subjects, natural history and risk factors remain 
largely unexplored. The detection rate of HPV in the oral mucosa presents a great variability 
(from 0% to 80%) in the different studies, and this can probably be explained by the 
difference in sensitivity of the techniques, by the limited size of the sample analyzed and 
depending on the type and site of oral specimens (Tominga et al., 1996; Kellokoski et al., 
1992; Terai et al., 1999).  
Among the more than 100 identified genotypes of human papillomaviruses, 25 of them were 
detected in the oral cavity. In 2010, Kreimer and colleagues have conducted a systematic 
review of the literature concerning the data published on the prevalence of HPV in healthy 
subjects, showing that 4.5% of the healthy subjects analyzed was positive for any HPV. 
Moreover, HPV16 accounted for 28% of all HPV detected in the oral region and 3.5% of the 
healthy subjects analyzed was positive for high risk HPV (Kreimer et al., 2010). Several 
studies suggest there may be a synergy between periodontitis, oral human papillomavirus 
infection and oropharyngeal cancers (Pullos et al., 2015; Psyrri et al., 2008). One of the most 
reliable hypotheses for the association between periodontitis and human papillomavirus 
infection supports that specific pathogens cause a state of chronic inflammation that results in 
periodontitis (Horewicz et al., 2010). The constant state of inflammation of the periodontium 
and the consequent formation of periodontal pockets create a perfect microenvironment for 
the persistence of the virus (Tezal et al, 2012). Furthermore, periodontal pockets can be 
specifically a reservoir for HPV and more generally also for other viruses/bacteria (Hormia et 
al., 2005). The replication of the virus also contributes to the maintenance of the chronic 
inflammatory state, with the possibility of finding high viral loads in patients' saliva (Hubbers 
et al., 2015). On the other hand, the relationship is bidirectional, the infection of the oral 
epithelium by the human papillomaviruses leads to its hyperproliferation, which in turn 
causes pathological changes in the periodontium, supports the inflammation and progression 
of periodontitis (Tommasino et al., 2014; de Paula et al., 2000; Kim et al., 2006). As known, 
an important immunosuppressive state can lead to an increased susceptibility to viral infection 
or/and an increase in viral replication.  In the study of Adamopulous and colleagues, it has 
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reported that the prevalence of HPV is significantly higher in the saliva of HIV-positive 
patients than those from oral cancer patients (35.3% and 10.3% respectively) (Adamopulous 
et al., 2008). Also in another study on saliva of HIV-positive patients has been reported an 
elevate frequency of HPV (about 33%) (Cameron et al., 2005). Indeed, among oral 
complications in HIV-positive patients, there are two diseases determined by HPV, which are 
oral warts associated with HPV-32 and oral tumors associated with HPV-16 (Cameron et 
al.,2008).  
Another viral family may be implicated into the periodontitis pathogenesis is the 
Polyomaviridae family, small DNA viruses that can establish latency in the human host. To 
date, at least thirteen members of this family have been identified, some of them playing an 
etiological role in malignancies in immunosuppressed patients. In particular, very recently, 
Merkel cell polyomavirus was isolated from the skin of a patient affected by Merkel Cell 
carcinoma (MCC) showing its ability to cause most of the Merkel skin cancers (Feng et al., 
2008). Infection with Human Polyomaviruses has been recently categorized by the 
International Agency for Research in Cancer as “probable carcinogen”. Infections with BK 
and JC polyomaviruses have been classified as “possible carcinogens” with studies in humans 
showing inconsistent evidence for an association with cancers at various sites 
(Http://monographs.iarc.fr/ENG/Monographs/vol104/mono104). In particular, the newly 
discovered viruses, such as Human Polyomaviruses 6, 7, and 9, that are commonly part of the 
skin viroma of the human host, are probably also involved in numerous, various, and 
unknown, as well, disorders. Additionally, already in the 1960s, it had been shown that 
Polyomavirus infection was able to develop periodontal disease in experimental animals 
(Shklar et al., 1963, Cohen et al., 1964). Fleming and colleagues have described severe 
periodontal disease in mice infected by Polyomavirus. The animals showed periodontal 
alterations of varying degrees of importance, from gingival recession, deep periodontal 
pockets formation to wide bone resorption. Furthermore, some Human Polyomaviruses have 
been already found in the saliva of both transplanted patients and healthy subjects. Indeed, 
Robaina and colleagues, who have conducted a study on the saliva of immunocompetent 
subjects, have detected in the 24.3% of the saliva samples analyzed the presence of at least 
one of the Human Polyomaviruses screened (Robaina et al., 2013). In another study, they 
have reported a higher frequency of Human Polyomaviruses infection in the HIV-positive 
children than among the healthy controls (28.3% versus 10.0%) (Robaina et al., 2013). 
Instead, Freze Baez and colleagues have conducted a study on the saliva and oral biopsy of 
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both immunocompetent subject and renal transplant recipients. Among the viruses for which 
the samples were screened, including several HHV, Merkel Cell Polyomavirus was the one 
that showed a predominant prevalence. Moreover, its genome was detected predominantly in 
the saliva of subjects with oral lesion (33.3%), such as gingivitis or periodontitis, of both 
healthy and transplant groups, and in the saliva samples of immunosuppressed patients 
(36.7%) (Freze Baez et al., 2013). Also Loyo et al.  have described high titers of Merkel Cell 
Polyomavirus in the saliva samples (Loyo et al., 2010). Another study has described the 
presence of BK Polyomavirus in the saliva collected from HIV-positive and negative subjects 
(Jeffers et al., 2009). Only few studies are available providing evidence that head and neck 
cancers (HNSCCs), a heterogeneous groups of tumors including oral cavity cancers, might be 
associated with Human Polyomaviruses (Kutsuna et al., 2008; Polz et al., 2015; Polz-Gruszka 
et al., 2015; Poluschkin et al., 2018).  Unfortunately, the number of studies concerning 
Human Polyomaviruses and the oral cavity is extremely limited (Table 3). Whether they are 
simple bystanders or are involved in the pathogenesis of some oral cavity diseases is 
completely unknown.  
Table 3. Prevalence of Human Polyomaviruses (HPyVs) in healthy and immunocompromised subjects 
Virus 
Control group 
% positive 
sample 
Case group 
% positive 
sample 
HPyV Sourse Reference 
Human 
Polyomavirus 
(HPyV) 
15% 37% MCPyV 
Saliva Freze Baez et al., 
2013 
12% 14% JCPyV Saliva Martelli et al., 2018 
3% 4% BKPyV Saliva Martelli et al., 2018 
8% 0% MCPyV Saliva Martelli et al., 2018 
7% - BKPyV Saliva Robaina et al., 2013 
0.3% - JCPyV Saliva Robaina et al., 2013 
13% - WUV Saliva Robaina et al., 2013 
2% - KIPyV Saliva Robaina et al., 2013 
- 0% JCPyV Oral Matos et al., 2012 
0% 5% BKPyV Saliva Robaina et al., 2013 
7% 3% JCPyV Saliva Robaina et al., 2013 
2% 2% WUPyV Saliva Robaina et al., 2013 
0% 13% KIPyV Saliva Robaina et al., 2013 
28% 10% HPyVs Saliva Robaina et al., 2013 
0% 0% JCPyV Saliva  Berger et al., 2006 
0% 0% 
JCPyV Saliva Sundsfjord et al., 
1994 
0% 0% 
BKPyV Saliva Sundsfjord et al., 
1994 
50% 50% BKPyV Saliva Castro et al., 2017 
0% 8% JCPyV Saliva Castro et al., 2017 
MEDIAN 3% 4% 
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2.1 HUMAN POLYOMAVIRUSES 
Initially, according to taxonomy, Polyomaviruses (PyVs) were classified as a genus of the 
Papovaviridae family together with Papillomaviruses; afterwards in 2000, in-depth studies 
have shown that the two groups have few similar sequences and have been recognized by the 
International Committee on Virus Taxonomy that has formally divided this family into two 
new separate families: Polyomaviridae and Papillomaviridae.  
PyVs are small, naked viruses able to infect a large number of vertebrates. Viruses belonging 
to this family have many common characteristics: the absence of envelope, a capsid with 
icosahedral symmetry with a diameter of about 45 nm and a genome consisting of a double 
stranded circular DNA molecule of approximately 5 Kb. 
The first identified PyVs was the murine polyomavirus (MPyV), ubiquitous in the mouse, 
capable of inducing tumors in newborn or immunosuppressed mice (Stewart et al., 1958). 
Indeed, the name of the family derives from this particular characteristic, and is formed by the 
Greek root "poly-" which means "many" and the ending "-oma" which means "tumors".  The 
next one that was identified, in 1960, was the simian virus 40 (SV40), isolated for the first 
time from monkey kidney cells. Similarly, to MPyV, SV40 proved capable of inducing 
tumors in mice and rodents (Sweet et al., 1960). In the following years, following an 
increased interest in these viruses, PyVs have been isolated from many other guests, such as 
birds, cats, rabbits and humans. Until 2007, the only PyVs known able to infect the humans 
were JC virus (JCPyV) and BK virus (BKPyV). Due to improvements in molecular diagnostic 
techniques, many other Human Polyomaviruses (HPyVs) were discovered. So far, at least 13 
HPyVs have been identified and most of them are still orphan of any disease associations 
(Feltkamp et al., 2013; Mishra et al., 2014). 
JCPyV and BKPyV were isolated for the first time in 1971: the first one was found in the 
brain of a patient with Hodgkin's lymphoma and progressive multifocal leukoencephalopathy 
(PML) (Padgett BL et al., 1971), while the latter in the urine of a kidney transplant patient 
(Gardner et al., 1971). Karolinska Institute Polyomavirus (KIPyV) and Washington 
University Polyomavirus (WUPyV) were isolated from nasopharyngeal aspirates of children 
with respiratory tract infection (Allander et al., 2007; Gaynor et al., 2007); while Merkel Cell 
Polyomavirus (MCPyV) was identified in skin lesions of a rare carcinoma of Merkel cells 
(Feng et al., 2008). In 2010, other three HPyVs were discovered, Human Polyomavirus 6 
(HPyV6) and -7 (HPyV7) identified in skin samples of healthy subjects (Schowalter et al., 
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2010), and Trichodysplasia Spinulosa-Associated Polyomavirus (TSPyV) recognized as the 
etiologic agent of a rare skin disease called trichodispasia spinulosa (van der Meijden et al., 
2010). Human Polyomavirus 9 (HPyV9) was detected in both serum and skin (Scuda et al., 
2011), Malawi Polyomavirus (MWPyV), also known as HPyV10 according to its order of 
discovery, was isolated from stool and skin samples of a Malawi patient affected by Warts, 
Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis syndrome (WHIM) 
(Siebrasse et al., 2012; Buck et al., 2012) and also Saint Louis Polyomavirus (SLPyV) was 
isolated from stool but from a healthy patient (Lim et al., 2013). The last two discovered 
polyomaviruses, the Human Polyomavirus 12 (HPyV12) and New Jersey Polyomavirus 
(NJPyV), were isolated respectively from the gastrointestinal tract tissues and muscle tissue 
of a pancreastransplanted patient (Korup et al., 2013; Mishra et al., 2014) (Table 4).    
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2.1.1 Virion structure 
HPyVs have a small icosahedral capsid with a diameter ranging between 40-50 nm. The 
structural viral proteins that compose it are called: viral protein 1 (VP1), the major capsid 
protein; VP2 and VP3, the two minor capsid proteins.  Indeed, the viral capsid consists of 360 
molecules of VP1 and 30-60 molecules of both minor structural proteins. The capsid is 
organized into 72 pentameric capsomers, each containing 5 molecules of VP1 and a molecule 
of VP2 or VP3 (Liddington et al., 1991; Griffith et al., 1992). Nevertheless, VP1 is the only 
protein exposed on the surface of the capsid and therefore it is responsible for virus 
attachment to host cell receptor, and this determines the receptor specificity (Figure 3). 
 
 
Figure 3. Structure of the icosahedral capsid of Human Polyomavirus 
 
2.1.2 Genome organization  
Within the capsid, the viral DNA is organized into a double-stranded, circular and super-
coiled molecule and has a length of about 5,000 pairs of bases. The genomic organization of 
the HPyVs is designed to enclose the maximum information (made up of 6 genes) in the 
smallest possible space (5 Kb). This is allowed by using both strands of the DNA molecule 
and overlapping genes. The nucleic acid is complexed with the histones H2A, H2B, H3 and 
H4 to give a chromatin complex (Louieet al., 1975; Keller et al., 1978). The viral genome 
contains two transcriptionally divergent units: a region called early, which encodes 
multifunctional regulatory proteins expressed in the early stage of infection, and a region 
called late, which encodes the three capsid proteins (VP1, VP2, VP3) expressed in permissive 
cells during the late phase of infection, and for a protein called agnoprotein. Furthermore, 
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there is a non-coding hypervariable regulatory region called non-coding control region 
(NCCR), located between the early and late transcription units (Cole et al, 2001; Moens et al., 
2001) (Figure 4). 
 
Figure 4. Schematic organization of the Human Polyomavirus genome 
The Early region is the first part of the genome to be transcribed and translated during the life 
cycle of the virus. It includes the genes coding two proteins called Large Tumor Antigen (T-
Ag) and Small Tumor Antigen (sT-Ag), which have the ability to reprogram the host cell to 
allow viral replication (Brodsky et al., 1998). These proteins are produced by alternative 
splicing of a common pre-mRNA. LT-Ag is a polyfunctional phosphoprotein, which during 
the productive infection determines the beginning of viral DNA synthesis, binding itself to the 
origin of replication. Furthermore, this protein determines the repression of early transcription 
and the stimulation of late transcription. The ability of LT-Ag to interfere in many different 
biological processes during the replicative cycle of the virus can be explained by the presence 
of different structural domains with distinct biochemical activities. Most of the information 
about the structure and the activity of LT-Ag, in particular regarding its transforming 
capacities, has been obtained from the SV40 studies (An P et al., 2012; Van Ghelue et al., 
2012). Through genetic and protein analysis, it has been demonstrated that all HPyVs’ LT-Ag 
have four conserved domains: DnaJ domain, origin-binding domain (OBD), zinc (Zn)-binding 
domain, and helicase/ATPase (adenosine triphosphatase) domain (An P et al., 2012; Van 
Ghelue et al., 2012; Topalis et al., 2013; 34. Kwun et al., 2009) (Fig 5). 
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Figure 5. Schematic organization of the functional domains of the HPyVs’ large tumor antigen (LT-Ag) 
and their main interactions with cellular factors (Baez CF et al.,2017) 
 
The DnaJ domain is located at the N-terminal of the LT-Ag, contains a HPDKGG motif 
which is able to bind to the Heat shock cognate 70 kDa protein (Hsc70), a cellular chaperone 
and transcriptional repressor; and a CR1 motif (LXXLL) is present only in BKPyV, JCPyV, 
and MCPyV (Whalen et al., 2005; Berjanskii et al., 2000; Chromy et L., 2003; Sheng et al., 
1997). The OBD domain is able to recognize GAGGC sequences and is an essential element 
for the beginning of viral replication; instead, the Zn-binding domain mediates the 
oligomerization of LT-Ag. The helicase/ATPase domain provides the energy for the helicase 
activity and in most of the HPyVs there is a conserved domain called p53-binding domain, 
responsible for the interaction of LT-Ag with the tumor-suppressor p53 (Lane et al., 1979; 
Meinke et al., 2016). 
The role of sT-Ag is different, which probably acts as an aid to the activity of T-Ag. 
However, the role of this protein has not been fully clarified, since there is experimental 
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evidence that has shown that viral replication is successful even in its absence (Eash S. et al., 
2007; White et al., 2015). sT-Ag has DnaJ domain, followed by a unique domain, that is 
eliminated from LT-Ag during the splicing process (Srinivasan et al., 1997; Whalen et al., 
1999; Kolzau et al., 1999) (Fig 6).  
 
 
Figure 6. Schematic organization of the functional domains of the HPyVs’ small tumor antigen (sT-Ag) 
and their main interactions with cellular factors (Baez CF et al.,2017) 
 
The Late region, on the other hand, contains genetic information for the synthesis of capsid 
structural proteins: the major VP1 protein and the two minor VP2 and VP3 proteins, which 
contain specific functional domains that facilitate the packaging of complete viral particles 
(Erickson et al., 2012). They derive from the same pre-mRNA by an alternative splicing 
process. The late region of the viral genome also encodes for the agnoprotein, whose role in 
the replicative cycle of human polyomaviruses remains to be clarified (Gerits et al., 2012).  
Finally, the NCCR is characterized by the presence of the origin of viral DNA replication, of 
both early and late promoters, of the enhancer regions, of the binding sites for the cellular 
transcription factors and of the LT-Ag binding sites (Lynch et al., 1990; Sock et al., 1993).  
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2.1.3 Lifecycle (attachment, entry and trafficking) 
Despite having a well-conserved structural organization, HPyVs have a narrow host variety 
and a particular cellular specificity; this seems to be due to the presence of characteristic 
receptors on the cell surface and the presence of specific cellular factors of the host, which 
allow the expression of viral genes and the completion of the viral life cycle. 
To start their life cycle, require the binding of their specific VP1 receptor to sialic acid, 
contained in glycoproteins or gangliosides present on the cell surface (Neu et al., 2012; 
Assetta et al., 2013; Schowalter et al., 2011). For example, for BKPyV the binding that allows 
the entry of the virus into the host cell has been identified: the studies conducted have 
suggested that the binding of the virus to the α (2,3) residues of sialic acid contained within 
the N-glycoproteins is sufficient to allow entry of the virus into the host cell (Dugan et al., 
2005). 
Following the adsorption of the virus to the membrane of the host cell, the virus is transported 
internally by endocytosis. In the case of BKPyV, the virus enters the cell rather slowly 
through a process of caveo-mediated endocytosis, lasting about four hours, and subsequently, 
anchoring itself to the microtubules and through the cytoskeletal transport system, reaches the 
nucleus (Eash et al., 2005). In contrast, it was demonstrated that JCPyV enters the host cell 
via a clathrin-dependent endocytosis mechanism (Querbeset al., 2006). 
At this point, the infection can proceed through two alternative routes: 
• Productive infection in permissive cells, with production of viral progeny and cell 
lysis; 
• Non-productive infection in non-permissive cells, which leads to the arrest of the 
replication cycle of the virus, preventing the replication of the viral genome and the 
expression of late genes. The arrest of DNA replication that occurs during non-
permissive infection may lead to either abortive infection or cell transformation. 
After entering the cytoplasm of the host cell, the virus goes to the nucleus. The passage inside 
the nucleus, instead, takes place through the nuclear pores of the nuclear membrane. In the 
nucleus, the process of scapsidation or uncoating takes place, which determines the exposure 
of the viral genome, followed by the expression and replication of the viral genome. In the 
case of most HPyVs, viral DNA does not integrate into the genome of the host cell, but 
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remains in an episomic form. The transcription process takes place by transcription apparatus 
of the host cell and follows a very precise order, defined by the organization of coding 
sequences: first the early genes are expressed, which through an alternative splicing process 
give rise to the two different mRNAs for the LT-Ag and st-Ag; subsequently LT-Ag promotes 
viral replication of DNA, thanks to its ability to bind to specific genomic sequences and to 
recruit the cellular proteins involved in the DNA synthesis process. Finally, the late genes are 
expressed, leading to the synthesis of capsid proteins. The resulting proteins return to the 
nucleus, where the new virions are assembled, they are observable as early as 24 hours after 
infection. The accumulation of viral particles determines the break of the nuclear membrane 
and the consequent release of the neo-assembled viral particles in the cytosol. The lysis of the 
cell membrane releases the infecting virions into the extracellular environment, where they 
can engage in a new replicative cycle. 
2.1.4 Molecular mechanism of transformation 
The oncogenic transformation is mediated by the early protein LT-Ag, through which the 
virus can bypass the cell cycle controls in order to replicate efficiently. Surely, one of the 
most important LT-Ag interactions is that with members of the pRB family (Van Ghelue et 
al., 2012; An P et al., 2012) 
The pRB protein product, encoded by the RB1 tumor suppressor gene, controls the G1 / S 
transition of the cell cycle (Di Fiore et al., 2013; Chinnam et al., 2011).  The hypo-
phosphorylated state of pRB is its active form capable to bind EF2, thus preventing cellular 
progression. Since this complex recalls a deacetylase, which, by increasing the state of 
compaction of chromatin, prevents the cellular transcription. The phosphorylated and inactive 
form of pRB, generated by the cyclin-dependent kinases (CDKs) - cyclin D complexes, on the 
other hand, is unable to bind EF2 and to inhibit cell cycle progression. E2F is therefore able to 
act as a transcription activation factor (Bertoli et al., 2013) (Figure 7, panel A). The 
interaction between LT-Ag and pRB proteins results in the activation of the transcription 
factors of the E2F family, which induce the expression of cellular genes essential for S-phase 
entry and DNA synthesis (Stubdal et al., 1997; Brown et al., 2002; Sullivan et al., 200; Lin et 
al., 2003) 
22 
 
 
Figure 7. HPyVs’ large tumor antigen (LT-Ag) oncogenic mechanisms. (A) In physiological conditions, the 
retinoblastoma proteins (pRbs) are in a hypophosphorylated state, which allows them to bind and inhibit 
the E2F transcription factors, preventing the E2F-mediated gene expression and consequently the 
transition from G1 to S phase. HPyVs’ LT-Ag is able to bind the pRbs promoting their 
hyperphosphorylation, thus pRb is unable to bind E2F, leading to its transcriptional activity; at the same 
time, the hyperphosphorylation of p130 disrupts the transcriptional repressor complex (p130- E2F4/5), 
leading to uncontrolled cell cycle progression and sometimes to malignant transformation. (B) Multiple 
cellular stress, normally, raises the levels of p53, which promotes the DNA repair and cell cycle arrest. 
HPyVs’ LT-Ag is able to bind and block the activity of p53 protein, preventing apoptosis and cell cycle 
arrest induced by DNA damage. 
Moreover, LT-Ag can also inactivate the tumor suppressor p53, promoting the transition of 
the cell from the G1 phase to the S phase and preventing the apoptotic phenomenon (Liu et 
al., 2015) (Figure 7, panel B). In a permissive host, this allows the production of viral 
progeny, followed by lysis and death of the host cell. In a non-permissive host, however, this 
may be a possible oncogenic factor, since the LT-Ag are expressed continuously without the 
viral cycle being completed. The p53 tumor suppressor plays a crucial role in cell cycle 
control. As a transcription factor, it mediates the expression of genes involved in cell growth, 
differentiation and proliferation processes (Harris et al., 2005). One of the main functions of 
p53 is the stimulation of p21 expression, which can promote cellular quiescence and induction 
of apoptosis, both intrinsically and extrinsically. The choice between quiescence and 
apoptosis is influenced by the extent of DNA damage and is mediated by proteins such as 
MYC, which can inhibit the expression of p21 favoring that of pro-apoptotic proteins. 
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Furthermore, p53 can also repress gene transcription by acting on E2F indirectly by p21 
(cyclin dependent kinase inhibitor), which inhibits the CDK-cyclin complexes, favoring the 
action of pRB (Xiong Y et al., 1993). The regulation of p53 is carried out above all at the 
level of its half-life through the action of the MDM2 protein, induced by p53 itself. It 
promotes the degradation of p53 by ubiquitination. MDM2 is inhibited by p14ARF induced 
by E2F (Lahav et al., 2004; Brown et al., 2009). The most reliable hypothesis concerning the 
interaction between p53 and LT-Ag supports that LT-Ag is able to associate itself with p53 by 
sequestering and inactivating it. The expression of LT-Ag and the consequent inactivation of 
p53 mimics, therefore, the same phenotypic effect that is caused by mutations affecting this 
tumor suppressor (Das et al., 2007). It is interesting to note that some viral oncoproteins, such 
as E6 of HPV, act on p53 degrading it, while LT-Ag leads to the accumulation of p53, 
stabilizing it as a p53-T-Ag complex (Russo et al., 2008; Das et al., 2007). 
3.1 HUMAN PAPILLOMAVIRUSES (HPV)  
Papillomaviruses represent a diverse and large group of species-specific and tissue-specific 
viruses, which are widespread among mammals but are also capable of infecting reptiles and 
birds (Bernard et al., 1994). As already described above, until the early 80s, Papillomaviruses 
were classified together with PyVs in the Papoviridae family; however, later studies showed 
that the initial similarities found were small compared to their differences. Thus two distinct 
families were defined: Polyomaviridae, to which the PyVs belong, and Papillomaviridae, to 
which the Papillomavirus belong. Based on the study of the entire genome, the International 
Agency for Cancer Research (IARC) described 189 genotypes of Papillomavirus. Of these, 
120 are human tropicviruses, called Human Papillomavirus (HPV), 64 infecting non-human 
mammals (rabbits, dogs, cats, horses), 3 birds and 2 reptiles (de Villiers et al., 2004). 
Moreover, the use of phylogenetic algorithms, able to compare multiple genomic sequences, 
has allowed to divide Papillomavirus types into 29 genera (from the genus Alpha 
Papillomavirus to the genus Dyoiota Papillomavirus) based on the percentage of similarity at 
the nucleotide sequence of the Open Reading Frame (ORF) of the capsid major protein (L1) 
(Bernard et al., 2010).  HPVs belong to 5 of these genera: α, β, γ, µ and ν. Each genus is 
subdivided into different species, which include viruses with a sequence homology in L1 
between 60% and 70%; within each species there are genotypes (or types) with a sequence 
similarity between 71% and 89%. Viruses with a homology greater than 90% but less than 
98% are defined subtypes; while those with a homology of 98% - 99% are called variants. 
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Based on the tropism of the virus, HPVs are divided into two broad categories: skin HPV and 
mucosal HPV. The former infects the keratinized epithelium causing skin lesions such as 
common warts frequently found at the level of the hands and feet. The latter infect the 
mucosal epithelium of the ano-genital tract, of the urinary tract, of the oral cavity and of the 
respiratory tract. Lesions of the mucosa are mainly represented by benign neoformations 
called condylomas. In addition, mucosal HPVs are also associated with squamous 
intraepithelial lesions that may progress to invasive squamous carcinoma (Murray PR and RH 
et al., 2003). Mucosal-genital HPVs are also classified, based on their ability to develop 
cancerous lesions in humans, in high (high-risk, HR) and low (low-risk, LR) oncogenic risk 
genotypes. 
3.1.1 Virion structure 
HPVs are naked viruses, lacking of lipoprotein coating (pericapsid), have an icosahedral 
capsid with a diameter of 45-55 nm, within is contained the viral genome, which consists of a 
circular closed molecule of DNA of about 8000 base pairs. The capsid is formed by the 
repetition of two proteins, L1 and L2: organized in 72 capsomers, for a total size of about 55 
nanometers (Modis et al., 2002). 
3.1.2 Genome organization  
The structure and genomic organization of HPVs is highly conserved among the different 
genotypes. The viral genome consists of a single double stranded circular DNA molecule of 
about 8 kb. It is divided into 3 coding regions: an early region, consisting of 6 genes (E1, E2, 
E4, E5, E6 and E7); a late region, codifying for structural proteins (L1, L2); and finally a non-
coding regulatory region called “long control region” (LCR) or also "upstream regulatory 
region (URR), containing the origin of replication and the binding sites of the different 
transcription factors (Figure 8) (Narisawa-Saito et al., 2007; Munoz et al., 2006). 
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Figure 8. Schematic organization of the Human Papillomavirus genome 
 
The 6 early genes encode for as many regulatory proteins, each of them with a specific 
function during the replicative cycle of the virus. E1 and E2 proteins are involved in viral 
replication and transcription (Hughes FJ et al., 1993). E1 is a phosphoprotein, which has ATP-
asic and helicase activity necessary to recognize and bind the origin of viral replication. 
Instead, E2 is a dimeric protein, which is able to positively or negatively regulate the 
expression of early genes. In fact, when the E2 protein is expressed at low levels it is able to 
activate the early promoters and thus favour the expression of early proteins; however, if 
expressed at high levels, it represses their expression (Spalholz et al, 1987; Mohr et al., 1990; 
Wilson et al., 2002). 
The E4 protein is expressed in the late stages of viral infection, it is indeed involved in the 
release phase of the mature virions. It seems to interact with the cytoskeleton of the host cell, 
affecting its structural integrity, and thus favouring the release of the neo-formed virions in 
the extracellular environment (Doorbar et al., 1991; Wilson et al., 2005). The activity of the 
E5 is a hydrophobic protein that is localized on the Golgi membrane and on the cell 
membrane. It would seem able to stimulate cell proliferation at different levels: inducing 
activation of the epidermal growth factor’s receptor, promoting mitotic signal transduction 
through interaction with transcription factors, and contributing to the inactivation of the 
apoptotic process (Ashrafi et al., 2005). The proteins E6 and E7 are called oncogene proteins, 
in fact they are responsible for the transformation of the host cell. These oncogene proteins 
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act by inactivating two important tumor suppressor proteins: p53 and pRb. Thus leading to 
deregulation of the cell cycle and transformation of the host cell.  
On the other hand, the late proteins are structural proteins, which form the viral capsid. The 
L1 protein is the major capsidic protein, has a molecular weight of about 55 kDa; while L2 is 
the minor capsid protein and has a molecular weight of about 70 kDa. The L1 proteins self-
assemble into 72 pentamers, in which L2 proteins are intercalated, leading to the formation of 
complete virion. 
3.1.3 Lifecycle (attachment, entry and trafficking) 
The lifecycle of HPVs is strictly dependent on the state of differentiation in which is present 
its target cell, that is the epithelial cells of the skin or mucosa depending on the specific 
tropism of the considered genotype (Longworth et al., 2004; Stanley et al., 2007). The entry 
of the virus into the host is via micro-lesions of the skin or mucosa. The initial infection 
occurs in the cells of the basal layer. HPV adhesion on the surface of the host cell occurs 
through the interaction of the L1 capsid protein with specific cell receptors. Controversy 
exists as to the nature of the cell surface receptor that allows initial attachment of the virus to 
the cell, although most studies have suggested a dependence on the presence of heparin 
sulphate (Giroglou et al., 2001; Joyce et al., 1999). Following the adsorption of the virus to 
the membrane of the host cell, the virus is transported internally by the endocytosis of clathrin 
coated vesicles (Culp et al., 2004; Day et al., 2003; Selinka et al., 2007). 
Once HPV has entered the host cell, the uncoating phase takes place, by breaking the 
intracapsidic disulphide bonds, allowing viral DNA to be transported into the nucleus. 
In the initial stages of infection in the basal cells of the epithelium, the pattern of viral gene 
expression consists of the E1 and E2 proteins, which allow a high replication of the viral 
genome (up to 100 copies per cell) (Wilson et al., 2002) and facilitates the correct segregation 
of genomes during cell division (You et al., 2004). When the infected cell divides, one of the 
two daughter cells escapes from the basal layer and begins the differentiation process, while 
the other one remains in the basal layer and allows the maintenance of the latent and 
persistent infection. 
When the infected epithelial cell reaches the spinous layer of the epithelium the expression of 
the other early genes also begins (E4, E5, E6, E7) and the late promoter is activated (L1, L2) 
(Figure 9).  
27 
 
 
Figure 9. Schematic representation of the expression of HPV genes while the infected cell migrates to the 
epithelial surface. 
 
Then, in the granular layer begins the productive phase of the viral cycle, leading to a massive 
replication of the viral genome in spite of a clear reduction in cellular DNA synthesis and an 
increase of the expression of late genes. The formation of mature viral particles occurs only in 
the most superficial layers of the epithelium, in completely differentiated cells, within which 
the genomes of the viral progeny are encapsulated and then released externally exploiting the 
physiological cellular turnover (Doorbar et al., 2004, Stanley et al., 2007). 
3.1.4 Molecular mechanism of transformation 
In several papers, both in vitro and in vivo experiments, have been shown that the co-
expression of E6 and E7 proteins of high-risk HPV genotypes shows transforming capacities 
(Durst et al., 1987). E6 is able to alter numerous cellular functions. One of the main 
mechanisms by which E6 is able to promote cell transformation is the binding of the tumor 
suppressor p53. The binding of E6 to p53 is mediated by an ubiquitin cellular ligase called 
E3-associated E6 protein (E6-AP E3). In particular, while the binding of low-risk HPV E6 
protein has no effect on the stability of p53, the binding of high-risk HPV E6 accelerates the 
degradation of p53. This leads to the inhibition of p53 functions, such as G1 cycle arrest, 
repair of damaged DNA, and the induction of irreparably damaged cell apoptosis (Scheffner 
et al., 1990). E6 of high-risk genotypes may negatively regulate p53 also indirectly, inhibiting 
gene transcription through interaction with transcription factors, like p300 and CREB-binding 
protein (CBP) (Patel et al., 1999). Another pathway through which E6 is able to inhibit the 
apoptosis of the host cell is by induction of the degradation of c-Myc and Bak, which are pro-
apoptotic proteins belonging to the Bcl-2 family. Normally, c-Myc induces the cell apoptosis 
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through the activation of p14ARF, which binds mdm2 that increases the half-life of p53. 
Finally, E6 is able to activate, independently from p53, the telomerase leading to the 
immortalization of the infected cell (Figure 10). 
 
Figure 10. Functions of the E6 / E7 oncoproteins  
The transforming capacity of E7 is due to its interaction with members of the pRb tumor 
suppressor family (p105, p130, p107). The E7 protein of high-risk genotypes binds pRB 
members with higher affinity than low-risk genotypes (Gage et al., 1990). In a normal cell 
cycle, pRb is in a hypo-phosphorylated state in the G0 and G1 phases and in this phase, it acts 
binding and inactivating the transcriptional factor E2F and thus inhibiting the progression of 
the cell cycle. The E7 protein is able to sequester the hypo-phosphorylated form of pRB, with 
consequent activation of the E2F target genes, independently of the presence of growth 
factors such as the Epidermal Growth Factor (EGF) and the Platelet-Derived Growth Factor 
(PDGF) (Gonzalez et al., 2001; Zhang et al., 2006). Therefore, the action of E7 leads to an 
uncontrolled proliferation of the infected host cell. 
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AIM OF THE STUDY 
The human oral cavity of healthy subject is strongly colonized by microorganisms, including 
viruses, bacteria, fungi and protozoa. Many of these are commensal species, which maintains 
health status when in equilibrium, but can become pathogenetic in response to specific 
ecological shift in the microbiome, such as poor oral hygiene, immunological disorders and 
specific genetic components. So far, there have been several studies about the involvement of 
the bacterial component of the oral cavity in the onset and development of oral diseases, but 
very few studies concerning oral viroma. In the present study, we have evaluated the 
prevalence of the DNA viruses mostly involved in the composition of the oral cavity viroma, 
that are the human Papillomaviruses and Polyomaviruses. The case study comprised both 
healthy subjects, without or with periodontitis and HIV positive patients. Nucleic acids 
isolation from saliva, buccal swab and paper points and subsequent Real Time PCR were the 
employed techniques. 
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4.1 CASE STUDY 
The study was carried out on clinical specimens collected from patients referring to the Dental 
Center of the Galeazzi Orthopedic Institute at Milan and to the Dental School of Temple 
University at Philadelphia. Saliva and buccal swab and when possible paper point were 
collected from 20 HIV positive patients (HIV+) without any buccal disease, 39 HIV negative 
subjects, 9 of which affected with periodontitis (PP). In addition, only buccal swab was 
collected from 66 HIV negative subjects referring to the Burlo Garofalo Institute at Trieste 
(Table 5). The local ethics committee approved the study and all patients or patients’parents 
gave their written informed consent (from the ethics committee of Temple University with the 
protocol number:24366, from the ethics committee of San Raffaele hospital with the protocol 
number: HPV-PI e registration number: 81/int/2016). 
          Table 5. Demographic and clinical data of enrolled patients and controls. 
HIV status Groups N° Male (%) Mean age ± ds 
HIV+ HIV+ 20 13 (65.0%) 54.1 ± 7.0 
HIV- 
HS 96 83 (86.5%) 37.7 ± 12.6 
PP 9 2 (22.2%) 50.3 ± 12.3 
HS: Healthy Subjects; PP: Subjects affected with periodontitis  
As shown in table 6, regarding the group of HIV positive patients, saliva samples and buccal 
swab samples could be collected for all 20 patients, but not the paper points samples. On the 
contrary, 39 saliva samples, 105 buccal swab samples and 19 paper points samples were 
collected from the 105 subjects enrolled in the healthy control group. 
          Table 6. Type and number of samples collected from enrolled patients and controls. 
HIV status Groups Saliva Buccal Swab Paper Points 
HIV+ HIV+ 20 20 - 
HIV- 
HS 30 96 10 
PP 9 9 9 
HS: Healthy Subjects; PP: Subjects affected with periodontitis  
4.2 BUCCAL SWAB USE AND DNA ISOLATION 
Specific buccal swabs were used to collect the oral samples, designed to increase yields and 
quality of DNA from buccal cells. To efficiently collect buccal cell samples is necessary to 
insert the swab into the mouth and rub along the entire surface of the tongue for at least one 
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minute. At this point, the buccal swab is placed in a tube containing a silica gel capsule, 
which placed in contact with the sample guarantees the long-term stability of the buccal DNA 
on the head of the swab before arrival in the laboratory. Before proceeding with DNA 
extraction it is necessary to remove the silica gel capsule from the tube. 
The viral DNA was extracted from buccal swab using the commercial kit Isohelix Buccal-
Prep Plus DNA (Isohelix). Before proceeding with DNA extraction it is necessary to remove 
the silica gel capsule from the tube, and add 500 µL of BLS solution to the tube containing 
the buccal swab, seal the tube then vortex. Thus the DNA is stabilized and it is possible either 
to proceed directly with the extraction or to store it at room temperature for up to a year 
without risking damaging the sample. Proceeding with extraction, it is necessary to add 20 µL 
proteinase K solution to the tube containing the buccal swab and BLS solution and briefly 
vortex. Incubate the tube at 60 ° C in a bath for one hour. Proteinase K is a serinquinase 
capable of degrading proteins, which having aromatic groups capable of absorbing ultraviolet 
light as well as nucleic acids, can interfere in reading the concentration of DNA in the 
spectrophotometer and in subsequent analytical analyzes. At the end of incubation, remove 
the swab head and add 400 µL BP solution, which consents the precipitation of DNA. Place 
the tube in a microcentrifuge and spin at maximum speed for 10 minutes. The pellet will 
contain the DNA. Remove the supernatant carefully, re-suspend the pellet in 50 µL of H2O 
and incubate for one hour at room temperature. After the incubation time is complete, re-spin 
the sample for 15 minutes at maximum speed to remove the insoluble impurities. Transfer the 
supernatant, containing the DNA, to a new sterile Eppendorf, being careful not to touch the 
pellet. The viral DNA is then quantified by spectrophotometry and stored at -20 ° C until the 
subsequent analytical procedures are performed. 
4.3 SALIVA COLLECTION AND DNA ISOLATION 
For the saliva collection, it was used the Salivette® (Sarstedt) kit, that contains a cotton swab, 
which provides an optimal method for hygienic collection of saliva.  The swab is removed 
from the Salivette®, placed into the mouth of the patient and chews for about 60 seconds to 
stimulate the salivation. Then, the swab with the adsorbed saliva is returned to the Salivette®. 
The Salivette® is then spinned at 1000 g for 2 minutes, which allows to collect a sample of 
clear saliva, that can be used for the analysis. 
The viral DNA was extracted from saliva using the commercial kit NucleoSpin RNA Virus 
(Macherey-Nagel). 
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The protocol, based on the principle of chromatography, provides the lysis of the sample 
under denaturing conditions, followed by a selective adsorption of the DNA to the silica 
matrix, subsequent washing and final elution. The extraction is performed using 150µl of 
sample (serum or urine), to which 600µl of RAV1, a lysis buffer and 20µl of proteinase K are 
added, in order to solubilize the membrane. The sample is then vortexed and subjected to an 
incubation of 70 ° C for 5 minutes. Subsequently, the precipitation of DNA is obtained by 
adding 600 µl of ethanol. The solution is loaded onto the spin column and the DNA binds to 
the silica membrane, while the remaining lysate is removed by centrifugation. 
Potential contaminants such as salts, metabolites and soluble macromolecular components of 
the cell membrane are removed through three serial washes with two specific buffers. 
The first wash is carried out by adding 500 µL of RAW buffer, while the last two involve the 
use of the same RAV3 wash buffer (600µL and 200µL respectively), for the elimination of 
any ethanol residues and contaminants. The column, at the end of the washings, is incubated 
at 70 ° C for 1 minute. Following incubation, 50µl of pre-heated RNAse-free water are added 
directly onto the membrane in order to elute the extracted DNA. The properties of the spin 
column matrix and the speed of microcentrifugation allow to obtain pure viral DNA in 
satisfactory quantities for subsequent analyzes. The DNA is then quantified by 
spectrophotometry and stored at the temperature of -20 ° C until the execution of the subsequent 
analytical procedures. 
4.4 PAPER POINT USE AND DNA ISOLATION 
For the sampling of the biofilm present in the subgingival sulcus, the point of paper has been 
used. The paper points have been inserted in the subgingival sulcus, paying particular 
attention not to traumatize the junctional epithelium, and remove after 20 seconds. The 
collected paper points are stored in DNA-free tube with 500 µL di for each patient 6 paper 
points were collected. Regarding paper point samples, viral DNA extraction was performed 
using the QIAamp DNA Mini Kit (QIAGEN) commercial kit. The isolation of the genome is 
based on the property of the DNA to bind to inert supports. These silica supports or filters 
have hydroxyl groups which selectively bind the negative charges placed on the oxygen atoms 
of the DNA phosphate groups. They allow, therefore, the selective binding of DNA and the 
elimination of RNA and proteins by means of a series of washes with appropriate buffers. The 
DNA bound to the filter can subsequently be eluted by water or a buffer containing Tris-HCl. 
Up to 200 µl of sample must be used to perform the extraction, to these are added 180 µl of 
34 
 
ATL Buffer, a lysis buffer, and 20 µl of proteinase K. To ensure efficient lysis, it is essential 
that the sample and Buffer AL are mixed thoroughly to yield a homogeneous solution. The 
solution thus composed must therefore be incubated at 56°C for 10 min. 
 At the end of the incubation, 200 µl of 100% ethanol are added to the sample to induce the 
precipitation of the DNA. The solution obtained is transferred to the QIAamp Mini Spin 
Column, a column characterized by the presence of a positively charged silica filter, which 
retains the DNA molecules (negatively charged). 
Following the DNA binding to the column two washes are carried out with two different 
buffers called AW1 and AW2. The first wash is carried out by adding 500 µl of Buffer AW1, 
which contains high salt concentrations, useful for eliminating the various cellular 
contaminants; the second washing, instead, is carried out by adding 500 µl of Buffer AW2, to 
eliminate the residuals of the previous buffer. Finally, we proceed with the elution of genomic 
DNA using 50µl of water deprived of enzymes with a nuclease action (DNAase free). The 
viral DNA is then quantified by spectrophotometry and stored at -20 ° C until the subsequent 
analytical procedures are performed. 
4.5 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION 
The quantitative Real Time - PCR (Q-PCR) is a specific technique, sensitive and applicable to 
biological samples of different nature and high number. The Q-PCR monitors the 
fluorescence emitted during the reaction as an indicator of amplified production during each 
PCR cycle and, therefore, operates in real time, unlike conventional PCR methods, which 
determine the final product. 
There are two general methods for quantitative analysis of the amplification: fluorescent 
probes, such as TaqMan probes, and double-strand DNA intercalation agents, such as SYBR 
green. In our study we use the TaqMan probes, which yield the 5'exonuclease activity of Taq 
polymerase. They are oligonucleotides 20-30 bases long, which contain a fluorescent marker, 
called "reporter", bound to the 5 'end, and a fluorescence repressor molecule, called 
"quencher", linked to the 3' base. TaqMan probes are designed based on the nucleotide 
sequence of the internal region of the PCR product. When the probe is intact and is excited by 
a light source, the fluorescence emission by the reporter is suppressed by the quencher, by the 
fluorescence resonance energy transfer property (FRET, due to the proximity of the two 
molecules.) When the probe binds to the template and is reached by the DNA polymerase, 
which is synthesizing the new strand of DNA, is cut off by the 5 'exonuclease activity of the 
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enzyme. As a consequence, the reporter separates from the quencher and the increase in their 
distance prevents the energy transfer allowing, thus, the reporter, to emit fluorescence. 
The increase in the signal emitted by the fluorescent molecule, which is proportional to the 
amount of amplified obtained, is read and converted by the instrument into an electrical signal 
and shown by the software by means of an amplification chart. 
To have high standards of specificity and sensitivity, the probe and the primers must have a 
content of C and G not higher than 80%, because it can interfere with the process of 
denaturation, annealing, extension and emission of fluorescence. The annealing temperature 
of the probe must be about 10 ° higher than that of the primers, so that it binds to the template 
before the primers. Finally, the probe and the primers must be designed in such a way as not 
to present complementary sequences, to prevent them bind to each other and form probe-
primer strands, or to form hairpin-shaped structures called "hairpin", all inside the individual 
filaments. 
Our machine is a 7500 Real-time PCR system (Applied Biosystems), consisting of a 
thermocycler, a halogen lamp for the excitation of fluorophores, and a CCD camera to capture 
the emitted fluorescence. The instrument is connected to a computer, supported by a suitable 
software, able to analyze the data related to the emitted fluorescence, with a wavelength 
between 500 and 600 nm. 
The amplification curve of a PCR product is theoretically exponential, but in reality, after the 
first phase, it assumes a rectilinear trend that progressively reaches a maximum value, called 
the plateau phase, to which all the samples tend, regardless of the quantity of Starting DNA 
due to the exhaustion of PCR reagents. 
In the study of a Real Time PCR graph, three basic parameters are defined: 
• Baseline region: it is the initial phase of the reaction, in which there are only non-significant 
variations in the fluorescence, called background noise (background). 
• Threshold: is the threshold line, which consists of the fluorescence value above which the 
signal is considered significant; it is chosen by the operator to intersect the curves of all the 
samples in the exponential phase. 
• Threshold Cycle, specific for each sample, identifies the value of the PCR cycle in which the 
curve in exponential phase intersects the threshold line. The threshold cycle (Ct = Cycle 
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threshold) is an important index because there is a linear relation between its value and the 
initial quantity of the reaction template. The quantification of the viral load of each sample 
can be made by amplifying serial dilutions of a standard of known DNA concentration, 
containing the target region to be amplified. This is necessary for the construction of a 
calibration line, defined as standard curve, with reference to which it will be possible to obtain 
the viral load values of each sample submitted to the analysis. 
 4.5.1 Duplex Real Time - PCR for JCPyV and HPyV6 
For the amplification and quantification of JCPyV and HPyV6 two sets of primers/probes 
targeting the T-Ag and the VP1 coding regions, respectively, were used (table 7) 
Table 7. Specific sequences of primers and probe of JCPyV and HPyV6 used in the Real Time PCR analysis. 
VIRUS 
TARGET 
REGION 
PRIMERS 
/PROBE 
POSITION SEQUENCE 
JCPyV T-Ag 
Forward 4299-4321 5’-GAGTGTTGGGATCCTGTGTTTTC-3’ 
Reverse 4352-4375 5’-GAGAAGTGGGATGAAGACCTGTTT-3’ 
Probe 4323-4350 5’FAM-TCATCACTGGCAAACATTTCTTCATGGC-MGB3’ 
HPyV6 VP1 
Forward 1767-1786 5’-GGCCTGGAAGGGCCTAGTAA -3’ 
Reverse 1847-1823 5’-ATTGGCAGCTGTAACTTGTTTTCTG -3’ 
Probe 1789-1806 5’JOE-AGAACCAACCATCTGTTG- BHQ1-3’ 
 
The reaction mix was prepared as follows (table 8): 
 
                             Table 8. Reaction mix setup. 
COMPONENTS FINAL CONCENTRATION 
Master Mix 1X 
Forward JCPyV 400 nM  
Reverse JCPyV 400 nM 
Taqman Probe JCPyV 150 nM 
Forward HPyV6 900 nM 
Reverse HPyV6 900 nM 
Taqman Probe HPyV6 250 nM 
DNA sample ≤ 250 ng 
H2O final volume of 20 µL 
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4.5.2 Duplex Real Time - PCR for BKPyV and MCPyV 
For the amplification and quantification of BKPyV and MCPyV, two sets of primers/probes 
targeting the VP1 coding regions, were used (Table 9). 
Table 9. Specific sequences of primers and probe of BKPyV and MCPyV used in the Real Time PCR analysis. 
VIRUS 
TARGET 
REGION 
PRIMERS 
/PROBE 
POSITION SEQUENCE 
BKPyV VP1 
Forward 2511-2531 5’-AGTGGATGGGCAGCCTATGTA-3’ 
Reverse 2586-2605 5’-TCATATCTGGGTCCCCTGGA -3’ 
Probe 2535-2556 5’VIC-TATGGAATCCCAGGTAGAAGA-MGB 3’ 
MCPyV VP1 
Forward 4053-4072 5’-GAGTGTTGGGATCCTGTGTTTTC-3’ 
Reverse 4090-4112 5’-GAGAAGTGGGATGAAGACCTGTTT -3’ 
Probe 4074-4089 5-FAM-TCATCACTGGCAAACATTTCTTCATGG C-MGB-3’ 
 
The reaction mix was prepared as follows (table 10): 
 
                             Table 10. Reaction mix setup. 
COMPONENTS FINAL CONCENTRATION 
Master Mix 1X 
Forward BKPyV 200 nM 
Reverse BKPyV 400 nM 
Taqman Probe BKPyV 150 nM 
Forward MCPyV 200 nM 
Reverse MCPyV 400 nM 
Taqman Probe MCPyV 200 nM 
DNA sample ≤ 250 ng 
H2O final volume of 20 µL 
 
4.5.3 Duplex Real Time - PCR for HPyV7 and HPyV9 
For the amplification and quantification of HPyV7 and HPyV9 two sets of primers/probes 
targeting the VP1 coding regions, were used (Table 11). 
 
38 
 
Table 11. Specific sequences of primers and probe of BKPyV and MCPyV used in the Real Time PCR analysis. 
VIRUS 
TARGET 
REGION 
PRIMERS 
/PROBE 
POSITION SEQUENCE 
HPyV7 VP1 
Forward 1774-1796 5’-AGGTCAATGAAGCCCTAGAAGGT-3’ 
Reverse 1840-1822 5’-TGCTTTCTGAGGGCTTGCA-3’ 
Probe 1798-1817 5’-FAM-CAGGCAATACTGATGTAGC-MGB-3’ 
HPyV9 VP1 
Forward 1449-1469 5’-CCCCAAAGAAAAGGCAAGAG -3’ 
Reverse 1509-1493 5’-GCGGGTGTTGGACAGGTTT-3’ 
Probe 1472-1488 5’-VIC-CGGAGCATGTCCTGTAA-MGB-3’ 
 
The reaction mix was prepared as follows (table 12): 
                             Table 12. Reaction mix setup. 
COMPONENTS FINAL CONCENTRATION 
Master Mix 1X 
Forward BKPyV 200 nM 
Reverse BKPyV 400 nM 
Taqman Probe BKPyV 150 nM 
Forward MCPyV 200 nM 
Reverse MCPyV 400 nM 
Taqman Probe MCPyV 200 nM 
DNA sample ≤ 250 ng 
H2O final volume of 20 µL 
 
For all the HPyVs’ Real Time PCR assays performed the cycling conditions were as follow 
(table 13)  
Table 13. Real Time PCR cycler conditions. 
STEP TIME TEMPERATURE 
Uracil-N-glycosylase activity 2 min 50°C 
PCR initial activation step 15 min 95°C 
Denaturation 15 sec 95°C 
Annealing 30 sec 60°C 
Number of cycles 40 
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4.5.4 Multiplex Real Time - PCR for HPVs  
For HPV analysis each DNA were subjected to a quantitative Real Time TaqMan PCR assay 
targeting seven high risk-HPV genotypes (HPV 16, 18, 31, 33, 45, 51 and 52). No 
information regarding the primer / probe sequence were available, since they are protected by 
a manufacturer’s patent.  
The reaction mix was prepared as follows (table 14): 
                             Table 14. Reaction mix setup. 
COMPONENTS FINAL CONCENTRATION 
TaqMan Gene Expression Master Mix 2X 1X 
HPVs Forward primers 400 nM 
HPVs Reverse primers 400 nM 
HPVs Taqman Probe  200nM 
DNA sample ≤ 250 ng 
H2O final volume of 20 µL 
 
In each plate negative controls (consisting of the mix with 5µl of H2O instead of the template) 
and standards for each of the studied viruses (dilution range: 101–104 plasmid copies/µl) were 
added.  
The reaction parameters of the quantitative Real Time PCR assays were as follow (table 15) 
Table 15. Real Time PCR cycler conditions. 
STEP TIME TEMPERATURE 
Uracil-N-glycosylase activity 2 min 50°C 
PCR initial activation step 10 min 95°C 
Denaturation 15 sec 95°C 
Annealing 30 sec 60°C 
Number of cycles 45 
 
4.5 STATISTICAL ANALYSIS 
Comparisons between groups of subjects and the subgroups of the oral specimens were done 
using the chi-square test or Fisher’s exact test. Unpaired t-tests were performed to evaluate the 
significant differences among the viral loads. Results were considered significant when the p 
values were less than 0.05. 
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5.1 QUANTITATIVE REAL-TIME PCR RESULT ON HPyVs 
Overall, 20 HIV positive patients and 105 HIV negative controls were included in this study. 
Demographic data of patients and control subjects is summarized in Table 5. 
Table 16 shows the results obtained by quantitative Real Time PCR assays, performed to 
evaluate the prevalence of the viral genome of 6 HPyVs (JCPyV, BKPyV, MCPyV, HPyV6, 
HPyV7, HPyV9) in the two groups of patients. 
 
    Table 16. Prevalence of HPyVs in HIV + and HIV- group of patients. 
 
Positive patients / total patients 
(%)  
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
7/20 * 
(35.0%) 
0/20 
(0.0%) 
9/20 ** 
(45.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
HIV- 
4/105 * 
(3.8%) 
1/105 
(1.0%) 
25/105 ** 
(23.8%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
1/105 
(1.0%) 
    * = p<0.05 
Prevalence of HPyVs in case and control groups was 60.0% (12/20) and 25.7% (27/105), 
respectively. Specifically, in the HIV positive group, 7/20 patients (35.0%) were positive for 
the JCPyV genome and 9/20 patients (45.0%) were positive for the MCPyV genome. Among 
these patients, 6 out 12 (50.0%) were coinfected by both viruses. 
The positive results were distributed as follows, among the healthy subjects: 4/105 (3.8%) 
were positive for JCPyV, 25/105 (23.8%) were positive for MCPyV, 1/105 (1.0%) was 
positive for BKPyV and 1/105 (1.0%) was positive for HPyV9. There were two cases of 
JCPyV and MCPyV concomitant infections, one case of BKPyV and MCPyV concomitant 
infection and one of HPyV9 and MCPyV. HPyV6 and HPyV7 were not isolated in any 
samples from either HIV positive and HIV negative subjects.  
The association between HIV infection and HPyVs positivity was statistically significant 
(p=0.015), even after adjusting for the presence of periodontitis disease (p=0.043). In 
particular, the different prevalence of JCPyV and MCPyV in the two groups of subjects was 
statistically significant, with a p value of 0.002 and 0.04 respectively. There was no evidence 
of differences in the viral load distributions between cases and controls (p=0.1604).  
Considering HIV negative patients and comparing patients affected with periodontitis (PP) 
with healthy subjects (HS), the percentages of infections were 11.1% (1/9) and 27.1 (26/96) 
respectively, with an odds ratio of 0.30 (Fisher exact test, p=0.684). Furthermore, within the 
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control group there is a significant difference between the positivity for JCPyV and MCPyV 
(p=0.001). 
5.1.1 Prevalence of HPyVs in saliva  
The subsequent analysis focused on the prevalence of HPyVs in the different types of oral 
samples (saliva, buccal swab and paper points). For this purpose, table 17 summarized the 
results in the saliva samples in the two different groups under analysis, while table 18 
summarized the mean viral load values of HPyVs. 
 
    Table 17. HPyVs detection in saliva samples of patients and control groups. 
 
Positive saliva samples / total saliva samples 
(%) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
5/20 
(25.0%) 
0/20 
(0.0%) 
9/20 
(45.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
HIV- 
4/39 * 
(13.8%) 
0/39 
(0.0%) 
12/39 * 
(41.4%) 
0/39 
(0.0%) 
0/39 
(0.0%) 
0/39 
(0.0%) 
TOTAL 
9/59 ** 
(15.3%) 
0/59 
(0.0%) 
21/59 ** 
(35.6%) 
0/59 
(0.0%) 
0/59 
(0.0%) 
0/59 
(0.0%) 
    * = p<0.05 
 
Table 18. Mean viral load of HPyVs in saliva samples of the enrolled patients and controls. 
 
Mean viral load copies/ml 
(range) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
3,22E+03 
(8,84E+03-2,50E+02) 
- 
1,06E+08 
(8,79E+08-5,36E+03) 
- - - 
HIV- 
1,53E+04 
(4,41E+04-3,29E+02) 
- 
5,57E+05 
(3,90E+06-6,26E+03) 
- - - 
 
Twelve/20 (60.0%) saliva samples collected from the HIV positive patient were positive for 
HPyVs; 5/20 (25.0%) saliva samples tested were positive for JCPyV (mean load 3,22E+03 
copies/mL; range 8,84E+03-2,50E+02 copies/mL), 9/20 (45.0%) were positive for MCPyV 
(mean load 1,06E+08 copies/mL; range 8,79E+08-5,36E+03 copies/mL). Among the 39 
saliva samples collected from the HIV negative control group, 14/39 (35.9%) were positive 
for HPyVs, and more specifically 4/39 (10.3%) were positive for JCPyV (mean viral load 
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1,53E+04 copies/mL; range (4,41E+04-3,29E+02 copies/mL) and 12/39 (30.8%) were 
positive for MCPyV (mean load 5,57E+05copies/mL; range 3,90E+06-6,26E+03 copies/mL). 
The difference between the prevalence of HPyVs in the saliva samples between the case and 
control groups was not statistically significant (p=0.562). On the contrary, overall, MCPyV 
was much more amplified in all the saliva samples, than JCPyV (p=0.02). This difference is 
mainly due to the higher prevalence of MCPyV genome, compared to JCPyV genome, in the 
saliva samples of HIV negative subjects (p=0.04). Considering HIV negative patients and 
comparing patients affected with periodontitis with healthy subjects, the percentages of 
infections were 0.0% (0/9) and 46.7% (14/30) respectively, with a p value of 0.015. There 
was no evidence of differences in the viral load distributions between cases and controls. 
5.1.1 Prevalence of HPyVs in buccal swab 
Table 19 and 20 summarized the prevalence of HPyVs in the buccal swabs samples and the 
mean viral load, respectively. 
Five/20 (25.0%) buccal swab samples collected from the HIV positive patient group were 
positive for HPyVs; 4/20 (20.0 %) buccal swab samples were positive for JCPyV (mean load 
1,55E+03 copies/mL; range 4,57E+03-3,63E+02 copies/mL), and 1/20 (5.0%) were positive 
for MCPyV (viral load 2,87E+05 copies/mL). Among the 85 buccal swab samples collected 
from the control group, 13/85 (15.3%) were positive for HPyVs, and more specifically 13/85 
(15.3%) were positive for MCPyV (mean viral load 1,39E+06 copies/mL; range 1,81E+07-
3,48E+03 copies/mL) and 1/85 (1.2%) were positive for BKPyV (mean load 
5,57E+05copies/mL; range 3,90E+06-6,26E+03 copies/mL). 
    Table 19. HPyVs detection in buccal swab samples of patients and control groups. 
 
Positive buccal swab samples / total buccal swab samples 
(%) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
4/20 * 
(20.0%) 
0/20 
(0.0%) 
1/20 
(5.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
HIV- 
0/85 * 
(0.0%) 
1/85 
(1.2%) 
13/85 
(15.3%) 
0/85 
(0.0%) 
0/85 
(0.0%) 
0/85 
(0.0%) 
TOTAL 
4/105 ** 
(3.8%) 
1/105 
(1.0%) 
14/105 ** 
(13.3%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
    * = p<0.05 
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Table 20. Mean viral load of HPyVs in buccal swab samples of the enrolled patients and controls. 
 
Mean viral load copies/ml 
(range) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
1,55E+03 
(4,57E+03-3,63E+02) 
- 2,87E+05 - - - 
HIV- - 3,84E-01 
1,39E+06 
(1,81E+07-3,48E+03) 
- - - 
 
The difference between the prevalence of HPyVs in the buccal swab samples of the case and 
control groups was not statistically significant (p= 0.327), as there was no evidence of 
differences in the viral load distributions (p= 0.556), but the positivity of JCPyV genome was 
significant different among the two groups (p=0.001). Additionally, considering all the 
analyzed samples of buccal swab, there was a statistical difference in the prevalence of 
JCPyV and MCPyV (p=0.024). In one HIV positive patients (5.0 %) and in one HIV negative 
(1.0 %) patients, MCPyV positivity was found in both saliva and buccal swab samples; and in 
two HIV positive patients (10.0 %) JCPyV positivity was found in both saliva and buccal 
swab samples. 
5.1.1 Prevalence of HPyVs in paper points 
Paper points samples were collected only from healthy subjects and the results are reported in 
tables 21 and 22. 
    Table 21. HPyV results in paper points samples of patients and control groups. 
 
Positive paper points samples / total buccal swab samples 
(%) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ - - - - - - 
HIV- 
0/19 
(0.0%) 
0/19 
(0.0%) 
3/19 
(15.8%) 
0/19 
(0.0%) 
0/19 
(0.0%) 
1/19 
(5.3%) 
TOTAL 
0/19 
(0.0%) 
0/19 
(0.0%) 
3/19 
(15.8%) 
0/19 
(0.0%) 
0/19 
(0.0%) 
1/19 
(5.3%) 
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Table 22. Mean viral load of HPyVs in paper points samples of the enrolled patients and controls. 
 
Mean viral load copies/ml 
(range) 
Group JCPyV BKPyV MCPyV HPyV6 HPyV7 HPyV9 
HIV+ 
- - - - - - 
HIV- - - 
2,44E+04 
(6,48E+04-4,26E+03) 
- - 2,30E+05 
 
Four/19 (21.0%) paper points samples were positive for HPyVs genome, and the positive 
results were distributed as follows: 3/19 (15.8%) were positive for MCPyV (mean viral load 
2,44E+04 copies/mL; range 6,48E+04-4,26E+03 copies/mL), one of which comes from a 
patient affected with periodontitis and two from healthy subjects; and 1/19 (5.3%) was 
positive for HPyV9 (viral load 2,30E+05 copies/mL). In one healthy subject (5.0 %) MCPyV 
positivity was found in both paper points and buccal swab samples. 
5.1 QUANTITATIVE REAL-TIME PCR RESULT ON HPV 
The results obtained showed the presence of 3 high risk-HPV genotypes (HPV 16, 51 and 52) 
in 2/20 (10.0%) HIV positive patients in the saliva samples. No positivity was reported in the 
control group (Table 23). 
    Table 23. Prevalence of HPVs in HIV + and HIV- group of patients. 
 
Positive patients / total patients 
(%) 
Group HPV16 HPV18 HPV31 HPV33 HPV45 HPV51 HPV52 
HIV+ 
1/20 
(5.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
0/20 
(0.0%) 
1/20 
(5.0%) 
1/20 
(5.0%) 
HIV- 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
0/105 
(0.0%) 
 
The HPV positivity resulted distributed as follow: co-infection of HPV-51 and 52 in a saliva 
sample and a single infection for HPV-16 in the other saliva sample. Viral load analysis 
revealed a viral load of 5,20*102 copies/mL and 6,4*101 copies/mL for HPV-51 and HPV-52 
respectively in the first saliva sample and 2,9*104 copies/mL for HPV-16 in the second saliva 
sample. 
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The oral cavity of healthy subjects is colonized by several and different microorganisms, such 
as viruses, bacteria, fungi and protozoa. Many of these are commensal species, which are 
essential to maintain a health status when in equilibrium with the environment, but can 
became pathogenic and capable to eliciting disease when occur environmental changes or 
shifts in the composition of the oral microbiota (Avila et al., 2015). The oral microbiota is 
involved in the onset and development of the two most common human oral diseases: dental 
caries and periodontal disease. Periodontal diseases include a group of chronic inflammatory 
diseases, that affect the periodontal supporting tissues of teeth and include destructive and 
nondestructive diseases (Armitage et al., 1999). Periodontitis is a multifactorial inflammatory 
disease of the periodontium that affects the majority of the adult worldwide (Albandar et al., 
2002; Nunn et al., 2003). The main factors responsible for the induction of the inflammatory 
state are oral microbiota and microbial products. It has been also shown that there are many 
other both local and systemic cofactors, which are able to increase the inflammatory state or 
the damaging effects induced by pathogenic microorganisms (Lindhe et al., 1975; Löe et al., 
1965). A better understanding of the etiopathogenesis of periodontal diseases seems to be 
essential to progress in risk assessment, in order to distinguish the factors that actually possess 
the true effects of risk modification from those that are risk indicators or are simply bystander 
factors, and to develop therapeutic strategies. Nevertheless, despite there are numerous studies 
concerning the bacterial communities inhabiting the oral cavity, there are very few studies 
defining the oral viral community and their role, if any, in the development of oral diseases. 
Among the viruses, Human herpesviruses (HHVs) are more studied in association with the 
periodontitis. Human cytomegalovirus (HCMV) and Epsten-Barr virus (EBV) have been 
proposed as probable risk factor of the aggressive periodontitis (Jakovljevis et al., 2014). 
Indeed, there is a high prevalence of these viruses, around 52%, in the oral cavity of patients 
affected with periodontitis compared to their presence in the healthy periodontium, about 8% 
(Slots et al., 2010). However, as can be seen in tables 1 and 2, there is a large discrepancy in 
the HHVs prevalence among the studies conducted on both healthy subjects and subjects 
affected by different degrees of periodontitis. Probably these variances are due primarily to 
the difference in the type of clinical specimens (saliva, oral biopsies, oral swabs, etc.), in the 
sampling procedures, as to date guidelines for the collection of the samples do not exist and in 
the different sensitivity of the techniques. 
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The limited number of studies conducted to establish a causal or causative role of viral 
infections in the development of periodontal diseases has provided rather inconclusive results. 
The only viral family that seems to play a relevant role in the oropharyngeal diseases is so far 
the one comprising the Human Papillomaviruses (HPVs), that are viruses already associated 
to different oropharyngeal cancers. Among the more than 100 identified HPV genotypes, 25 
of them were detected in the oral cavity. While the prevalence of these viruses in 
oropharyngeal cancers has increased up to 72% (Mehanna et al., 2013), their prevalence in 
oral specimens in healthy subjects and their possible role in the onset of oral diseases remain 
largely unexplored. Together with the Papillomaviridae family, another viral family that may 
be implicated into the periodontitis pathogenesis is the Polyomaviridae family. The peculiar 
characteristics of Human Polyomaviruses (HPyVs), such as their ability to establish latency in 
the host in different body districts, the recognized etiopathogenic role of some of them in 
inducing serious diseases in immunocompromised subjects and the recent classification as 
probable carcinogens, make these viruses excellent candidates as possible factors involved in 
the pathogenesis of oral diseases. One of the most valid hypothesis to justify a 
etiopathogenetic role, or more probably co-factorial role, of the viral infection in the 
periodontal diseases suggests that the establishment of specific pathogens in the oral cavity 
promotes a chronic inflammatory state, that leads to the development of periodontal 
pathologies (Horewicz et al., 2010). The persistence of the inflammation of the periodontium 
and the formation of periodontal pockets contribute to the development of an ideal 
microenvironment for the persistence of the viruses.  This correlation is bi-directional; indeed, 
the high viral replication in the periodontium contributes to the physio-pathological 
modifications of the oral cavity, which in turn contributes to the maintenance of oral 
inflammation and to the progression of the oral pathology. 
Given the increasing incidence of oral diseases and the very limited study of viral 
involvement in these disorders, our study was aimed to give new insights on the possible 
presence of HPyVs and HPVs in the oral mucosa of both healthy and immunodepressed 
subjects. We could observe that the prevalence of HPyVs was significantly higher in the 
group of HIV positive subjects (60.0%) compared to the control group (25.7%). These data 
are consistent with data reported in previous studies, where the incidence of HPyVs infections 
was relevant in immunodepressed patients. Nonetheless, oral mucosa infections are 
characteristic of the HIV diseases, since reduced immunity in these subjects facilitates the 
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occurrence of viral infections. Among the HPyVs, the most prevalent were MCPyV and 
JCPyV, while the other HPyVs were absent or amplified in only one subjects.  
When the oral specimens were analyzed singularly, it could be observed that 44% (26/59) of 
the analyzed saliva samples were positive for the presence of at least one HPyV. The 
frequency detected in our study is in line with the few papers reporting the finding of HPyV 
DNA in the saliva, that ranges from 0 to 50%. The main difference among the studies is the 
median, that usually lies between 3% and 4%, much lower than the prevalence found in our 
study. Interesting MCPyV genome was significantly more present in the saliva than all the 
other HPyVs. Previously, Freze Beaz and collegues detected MCPyV genome in the saliva 
and in the oral lesions of immunocompetent subjects and transplanted patients. The authors 
concluded that the predominant detection of MCPyV in the saliva of immunodepressed 
subjects could have been considered as a consequence of the impairment of the immune 
system. Additionally, they stated that the presence of the virus in the oral lesions of both 
immunocompetent and immunosuppressed subjects could suggest the involvement of MCPyV 
in the onset and development of oral lesions. The data suggests an association between the 
presence of MCPyV and the oral cavity. Loyo et al. described the presence of high titer of 
MCPyV in the saliva samples of subjects without Merkel Cell Carcinoma (Loyo et al., 2010). 
On the other hand, there are some studies carried out on healthy subjects and 
immunocompromised patients that did not report the presence of any HPyVs (Matos et al., 
2012; Berger et al., 2006; Sundsfjord et al., 1994). Although different cell types may be 
collected during sampling, including the lymphocytes in which HPyVs are able to replicate, 
the viral load found in the tested samples was too high to be due to a random presence of the 
viruses: the author hypothesis that the oral cavity may be a site of viral replication.  
Based on our results, we could conclude that MCPyV may be part of the normal viroma of the 
oral cavity. Nonetheless, its well-known association with the Merkel Cell carcinoma leads to 
state that its presence should be monitored, in order to verify whether an association between 
MCPyV and oral diseases can be rule out. 
Regarding the results on the buccal swab samples, the total positivity for the presence of 
HPyVs was 17% (18/105) and also in this case MCPyV genome was the one detected at the 
highest percentage (13.3%), with high viral load. Furthermore, a positivity match for MCPyV 
genome in the saliva sample and in the buccal swab was found for both an HIV positive and a 
healthy patient.  Interestingly, JCPyV was present in 4 HIV+ buccal swabs and in none of the 
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healthy subjects buccal swabs. Finally, as regard the paper points samples, 21% (4/19) of the 
analyzed paper point samples were positive for the presence of at least one HPyVs. Also in 
this case MCPyV was the most evalent, having been found in 3 out of 4 positive samples, and 
there was a correspondence for a healthy subject between the buccal swab sample and the 
paper points sample. Unfortunately, no comparison could be made with other results since no 
paper has been focused on buccal swabs or paper points samples. 
Since HPVs infection has been strongly associated to different oropharyngeal cancers and 
prevalence of them in the oral cavity has not yet been studied, our investigation was extended 
to this family of viruses to evaluate their possible contribution.  Our results showed the 
presence of three high risk-HPV genotypes (HPV 16, 51 and 52) in 2/20 HIV positive 
subjects only in the saliva samples. No positivity was reported for any other type of samples 
and for any healthy subjects. 
This study demonstrated the wide presence of MCPyV in oral samples, in both healthy and 
immunodepressed subjects. There are some limits in this study: a) the limited case study; b) 
the failure to collect paper points from immunocompromised patients; b) the lack of a group 
of patients affected by different types of oral pathologies and subjects with a state of 
immunosuppression of different origins. 
However, to our knowledge, this is the first study to examine and compare the presence of 
HPyVs and HPVs in a broad range of oral sample types. The results here presented represent 
good basis for better and more thoroughly investigation on the role of viruses, and especially 
on MCPyV as part of the normal viroma of the oral cavity or as opportunistic agent involved 
in oral diseases. In the first case, it could be of interest also studying the interaction with other 
viruses or bacteria in the oral cavity. In the second case, future advances in the prevention of 
oral manifestations of these viruses can alert clinicians about oral opportunistic diseases and 
help them to control viral infection more efficiently especially in immunocompromised 
subjects.
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A B S T R A C T
Natalizumab greatly reduces inﬂammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated
leukocyte traﬃc to the brain, but less is known about its eﬀects on the systemic immunity. We measured 48
cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-
10, IL1ra) and pro-inﬂammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations
to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC
(JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major
risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic
immunity.
1. Introduction
The transmigration of autoreactive-activated T cells from peripheral
blood into the central nervous system (CNS) is a crucial step in the
initiation and maintenance of brain inﬂammatory reaction in multiple
sclerosis (MS) (Steinman et al., 2002). The α4β1-integrin (VLA-4), ex-
pressed on the leukocytes' surface and interacting with the vascular cell
adhesion molecule 1 (VCAM-1), is critically involved in this process
because it mediates both the adhesion and migration of lymphocytes
across the blood-brain barrier (BBB) (Kumar et al., 2005; Kummer and
Ginsberg, 2006; Libbey and Fujinami, 2010; Polman et al., 2006; Rose
et al., 2002; Sawcer et al., 2011).
Natalizumab is a monoclonal antibody directed against the α4 chain
of the VLA-4 and α4β7 integrins and is used as a monotherapy for
treating relapsing-remitting MS (RRMS)·(Stuve and Bennett, 2007).
Natalizumab substantially reduces the relapse rate and the worsening
symptoms, but its use is associated the development of progressive
multifocal leukoencephalopathy (PML), a fatal demyelinating disease
that occurs due to the lytic replication of the Polyomavirus JC (JCPyV)
(Polman et al., 2006).
Chemokines aﬀect the traﬃcking of leukocytes to the sites of in-
ﬂammation and have a crucial role in establishing a balance between
subpopulations of T helper (Th) cells (Baggiolini, 1998). Th2-related
cytokines are associated with inﬂammatory reduction and improve-
ment of MS symptoms. In contrast, Th1-related cytokines, which are
known as pro-inﬂammatory proteins are increased in brain, cere-
brospinal ﬂuid (CSF) and/or blood of MS patients, especially during
acute exacerbations (Imitola et al., 2005; Mellergard et al., 2010; Miller
et al., 2004; Sharief and Hentges, 1991).
The eﬀects of the cytokine/chemokine levels have been occasionally
analyzed, with contrasting results (Khademi et al., 2009; Kivisakk et al.,
2009; Mellergard et al., 2010; Ramos-Cejudo et al., 2011). To gain in-
creased insight into the immunomodulating eﬀect of natalizumab sys-
temically, we used a multiplex array to measure the levels of 48 cyto-
kines/chemokines in sera from MS patients treated with natalizumab
from 21 months.
2. Materials and methods
2.1. Patients and samples collection
After obtaining signed, informed consent based on the local ethics
committee guidelines, 19 patients with RRMS, treated with natali-
zumab, were enrolled at the “Fondazione Istituto Neurologico C.
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Mondino” (Pavia, Italy). Natalizumab was administered intravenously
to RRMS patients once every 4 weeks at a dose of 300 mg. Blood, serum
and urine samples were collected before the ﬁrst infusion (T0) and
subsequently after 12 (T12) and 21 (T21) months of treatment. At the
corresponding time point, Kurtzke's Expanded Disability Status Scale
(EDSS) was scored, and Magnetic Resonance Imaging (MRI) scans were
performed (Castellazzi et al., 2015).
2.2. Cytokines/chemokines analysis
Quantiﬁcation of 48-cytokines/chemokines was performed on the
serum samples at T0, T12 and T21 using magnetic bead-based multiplex
immunoassays (Bio-Plex®) (BIO-RAD Laboratories, Milano, Italy), fol-
lowing the manufacturer's instructions. This procedure uses Luminex
Xmap technology with magnetic multi-analyte proﬁling beads. Brieﬂy,
a standard curve was created via dilution of premixed standards to
50,000 pg/mL, followed by series dilution to 8 concentrations. 50 μL of
serum (diluted 1:4), and 50 μL of standard curve samples were added to
a 96-well ﬁlter plate containing anti-cytokine antibody-conjugated
beads. After incubation for 30 min at room temperature, followed by
washing plate with Bio-Plex Wash Buﬀer, 25 μL of the antibody-biotin
reporter was added and incubated for 30 min shaking at 1100 rpm, and
then 50 μL of Streptavidin-PE was added to each well. After incubation
of 10 min 125 μL of Bio-Plex assay Buﬀer was added to plate for
reading. The concentration of cytokines was determined by using the
Bio-Plex 100 Analyzer (Bio-Rad Laboratories, Hercules, CA) following
the manufacturer's instructions. A digital processor managed data
output, and the Bio-Plex Manager® software presented the data as
median ﬂuorescence intensity (MFI) and concentration (pg/mL) (BIO-
RAD Laboratories, Milano, Italy). These assays have a limit of detection
of 1–20 pg/mL, depending on the protein target.
Th2/Th1ratio was deﬁned based on the ratio of IL-4, IL-5, IL-6 or IL-
10 Th2 related cytokines and pro-inﬂammatory IFN-ɣ or TNF-α cyto-
kines Th1-related cytokines.
2.3. DNA extraction and JCPyV detection
DNA was isolated from 0.2 mL of blood samples using the
QIAampDNA Mini Kit (Qiagen, USA) and 0.15 mL of urine samples with
Nucleospin RNA Virus Kit (MachereyNagels, Germany) following the
manufacturer's instructions. Quantitative real time PCR (Q-PCR) assay
was performed to quantify JCPyV genome using a Taqman chemistry
with an Applied Biosystems 7500 Real-Time PCR System (Applied
Biosystems, Carlsbad, CA), with speciﬁc primers targeting the Large T
antigen viral region, following a protocol described previously
(Campello et al., 2011; Delbue et al., 2005). Data were expressed as
copies/μg of DNA isolated from blood and as copies/mL of urine sam-
ples.
2.4. Anti-JCPyV IgG antibodies in serum samples
Serum concentrations of anti-JCPyV IgG were measured using a
home-made ELISA previously described, using a GST-JCPyV VP1 pro-
tein as the capture antigen (Elia et al., 2016).
2.5. Statistical analysis
The values of the cytokines were analyzed under log transformation
considered the skewedness of the distributions. Linear mixed models
were used to analyze the change in time of the cytokines with a random
intercept for each patient. The same approach was used to compare the
values in time of the cytokines of patients with and without JCPyV
viruria with an interaction with time of the virus presence. The false
discovery rate was used to adjust the p-values, considering the multiple
testing problem due to the analysis of 48 cytokines. The same analysis
strategy was used to evaluate the change over time of the 8 Th2/Th1
ratios. Diﬀerences were considered signiﬁcant at p < 0.05 (CI 95%).
3. Results
3.1. Patient characteristics
A total of 19 RRMS patients treated with natalizumab for 21 months
was included in the study. Demographic and clinical characteristics are
described in Table 1.
3.2. Cytokine/chemokine proﬁle and natalizumab treatment
A panel of 48 soluble immune proteins was measured in the sera for
the evaluation of their expression proﬁle in response to natalizumab
treatment at T0, T12 and T21. The concentration of the molecules
measured as pg/mL, their role and the degree of statistical signiﬁcance
are reported in Table 2. Some of these proteins, including IL-2, IL-15,
RANTES, IL-1a, IL-12p40, β-NGF, TNF-β, GM-CSF, MCP-1 and IFN-α,
showed a concentration below the detection limit; therefore, they were
not considered in the analysis of results. The concentration of seven
molecules was signiﬁcantly increased (Eotaxin) or decreased (IL-1ra, IL-
7, IL-10, PDGFbb, IL-16 and HGF) during this time (Table 2 and Fig.1).
Th2/Th1 ratios did not exhibit any diﬀerences in the three analyzed
time points, except for the IL-10/IFN-ɣ and IL-10/TNF-α ratios (Fig. 2).
3.3. JCPyV DNA detection, seropositivity and natalizumab treatment
JCPyV DNA was not found in any of the blood samples (Data not
shown). No signiﬁcant changes were observed in the urine JCPyV viral
load or the levels of serum JCPyV antibodies (Fig. 3).
3.4. Cytokine/chemokine proﬁle and JCPyV detection
The cytokine proﬁles of patients with JCPyV viruria were compared
to those of patients without JCPyV viruria. No signiﬁcant diﬀerences
were observed for the considered cytokines (Data not shown).
Table 1
Demographic, clinical and radiological characteristics in 19 relapsing remitting multiple sclerosis (RRMS) patients receiving Natalizumab.
Demographic, clinical, and radiological characteristics in 19 RRMS patients receiving Natalizumab during 21 months of treatment
Sex (F/M) 16/3
Age at recruitment (mean ± SD) 34.2 ± 9.8
Disease duration at baseline (mean years ± SD) 10.2 ± 6.2
EDSS at baseline (mean ± SD) (range) 1.3 ± 1.5 (0.0–6.5)
EDSS after 12 months of treatment (mean ± SD) (range) 1.4 ± 1.6 (0.0–6.5)
EDSS after 21 months of treatment (mean ± SD) (range) 1.7 ± 1.7 (0.0–7.0)
Relapsing/non-relapsing patients 5/15
Patients with/without new MRI lesions at the end of treatment 4/15
EDSS = Expanded Disability Status Scale; MRI = Magnetic Resonance Imaging; SD = standard deviation.
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4. Discussion
The beneﬁcial eﬀects of natalizumab in MS patients are associated
with the reduction of the inﬂammatory status in the CNS (Jain et al.,
2010; Yednock et al., 1992).
The marked decline of the inﬂammation intrathecally indicates a
decline in the CSF levels of cytokines and chemokines, at both the
mRNA and protein levels after one year of treatment (Khademi et al.,
2009; Mellergard et al., 2010).
How natalizumab aﬀects the systemic status of inﬂammation is in-
stead less understood. Khademi and colleagues observed increases in
systemic pro-inﬂammatory cytokine expression (mRNA levels) after 6
and 12 months of treatment. The high levels of pro-inﬂammatory cy-
tokines in the blood were associated with the lymphocytosis and fa-
tigue, occurring in association with natalizumab treatment (Khademi
et al., 2009; Khademi et al., 2008). High numbers of activated T cells
expressing pro-inﬂammatory cytokines in blood have also been ob-
served (Khademi et al., 2009).
Opposite results were reported by Mellergard et al. (2010), who
showed a marked decline in circulating plasma GM-CSF, TNFα, IL6 and
IL 10 (proteins) after 12 months of treatment. In addition, it has been
reported that 20 months of treatment with the antibody did not modify
globally the cytokine proﬁle in the blood, although an increase in some
pro-inﬂammatory and anti-inﬂammatory cytokines has been observed
after starting treatment (IFN-ɣ, IL-4, IL-10, IL-5 and IL-13) and after
long-term treatment (IL-1β, IL-2, IL17,IL-5 and IL-13) with natali-
zumab. In addition, in the same study, the treatment with the antibody
did not modify regulatory T cell function. These ﬁndings suggested
diﬀerent mechanisms of action of early versus prolonged exposure to
Natalizumab on the target immune cells (Ramos-Cejudo et al., 2011).
Our study adds to this debate, given that the sera cytokine/che-
mokine proﬁles were deﬁned in 19 patients with clinically deﬁned
RRMS before the beginning of natalizumab treatment and after 12 and
21 months. It was not possible to conduct the same analysis on healthy
donor subjects in order to obtain data on biological variation and re-
ference range values.
Most of the 48 studied proteins did not exhibit any signiﬁcant
variations during the course of the treatment, except for IL7, IL16,
PDGFbb, HGF, IL1ra, and IL10, which decreased over 21 months. The
ﬁrst three listed proteins are pro-inﬂammatory, produced by Th1 cells,
whereas the last three proteins act as anti-inﬂammatory mediators,
secreted by Th2 cells. Despite these variations, the Th2/Th1 ratio was
not subjected to any changes at the three analyzed time points, except
for the IL-10/IFN-ɣ and IL-10/TNF-α ratios. Thus, the beneﬁcial eﬀect
of natalizumab cannot be associated with a shift in favor of a Th2 anti-
inﬂammatory proﬁle. These data had no clinical counterparts, as they
did not correlate with the clinical ﬁndings.
As for single cytokines, a signiﬁcant decrease in IL7, which is a non-
redundant cytokine for T-cell development and survival, has been ob-
served. Several reports have indicated that the IL-7 levels increased in
MS and experimental allergic encephalomyelitis (EAE) (Chou et al.,
1999). IL-7 enhances proliferation and IFN-γ secretion by myelin-acti-
vated T cells cultured from both normal controls and MS patients.
Consistent with our results, IFN-β1a treatment led to signiﬁcantly re-
duced serum IL-7 levels, whereas natalizumab treatment mitigated the
serum IL-7 levels (Lundstrom et al., 2014). Analogously to IL-7, IL-16 is
Table 2
Concentrations of immune mediators in serum of RRMS patients. Data are provided as the means (quartiles) (pg/mL).
Immune eﬀector cells Immune mediator Type of mediator T0 T12 T21 p value
Th1 IFN-ɣ Cytokine 59.2 (52.81–64.06) 59.2 (4779.73–6975.63) 55.99 (52.29–63.52) 0.756
IP-10 (CXCL10) Chemokine 7061.56 (4970.34–9298.59) 5854.6 (4779.73–6975.63) 6315.67 (4945–9174.54) 0.692
TNF-α Cytokine 65.53 (57.92–68.94) 67.23 (57.09–70.65) 66.38 (62.14–71.08) 0.756
MIG (CXCL9) Chemokine 374.82 (315.31–515.68) 351.74 (284.82–949.17) 402.24 (293.59–632.20) 0.756
Th2 IL-4 Cytokine 2.06 (1.88–2.43) 2.10 (1.95–2.37) 2.14 (1.84–2.22) 0.756
IL-5 Cytokine 0.53 (0.52–0.58) 0.53 (0.48–0.58) 0.53 (0.48–0.53) 0.240
IL-9 Cytokine 14.89 (10.95–23.66) 10.76 (8.94–15.18) 12.25 (7.78–14.51) 0.183
IL-13 Cytokine 2.21 (1.94–2.95) 2.08 (1.99–2.58) 2.05 (1.83–2.28) 0.494
Eotaxin (CCL11) Chemokine 644.54 (409.73–1237.20) 936.6 (523.71–2171.71) 1287.95 (755.12–2129.31) 0.004
Th17 IL-6 Cytokine 9.38 (8.55–10.97) 9.38 (8.30–10.27) 9.58 (8.40–10.47) 0.756
IL-8 (CXCL8) Cytokine 16.85 (12.41–24.66) 16.85 (10.88–36.91) 14.92 (10.95–41.79) 0.699
IL-17 Cytokine 16.77 (12.41–20.04) 13.09 (10.94–19.78) 13.34 (9.79–15.11) 0.146
T reg IL-10 Cytokine 1.97 (1.61–2.31) 1.70 (1.45–1.91) 1.65 (1.34–1.85) 0.035
B cells SDF-1α (CXCL12) Chemokine 38.71 (0.80–62.75) 38.71 (3.96–53.88) 25.87 (0.80–43.98) 0.437
Broad spectrum IL-7 Cytokine 1.07 (0.96–1.28) 0.98 (0.95–1.15) 0.93 (0.87–10.47) 0.034
IL-12p70 Cytokine 2.57 (2.01–3.36) 2.57 (1.95–2.97) 1.73 (1.39–3.24) 0.386
IL-18 Cytokine 53.2 (42.92–63.95) 52.68 (41.96–73.21) 52.68 (41.34–66.33) 0.592
SCF Trophic factor 38.19 (24.82–56.04) 31.28 (25.33–46.26) 30.25 (20.98–39.59) 0.768
SCGF-b Trophic factor 17,020.42 (6391.02–26,026.38) 13,811.04 (4132–17,700.1) 3265.03 (3138–11,627.08) 0.663
IL-1β Cytokine 1.05 (0.98–1.10) 1.06 (1.00–1.21) 1.00 (0.94–1.14) 0.699
G-CSF Trophic factor 25.14 (22.42–29.51) 22.42 (19.45–27.60) 21.88 (17.84–25.96) 0.153
Broad spectrum MIP-1α (CCL3) Chemokine 3.66 (3.36–4.17) 4.07 (3.37–4.70) 3.53 (3.40–4.03) 0.592
MIP-1β (CCL4) Chemokine 67.38 (47.22–99.94) 86.45 (49.86–129.76) 72.48 (49.54–113.04) 0.699
VEGF Trophic factor 14.69 (10.36–18.10) 9.29 (6.67–16.72) 8.21 (5.76–12.82) 0.153
IL-3 Cytokine 4.10 (4.10–6.68) 4.10 (4.10–4.10) 4.10 (4.10–4.10) 0.757
IL-16 Cytokine 33.33 (16.59–46.43) 21.38 (9.07–41.67) 12.38 (7.56–19.29) 0.041
CTACK (CCL27) Chemokine 482.82 (363.93–636.02) 414.88 (364.75–544.42) 419.4 (329.35–490.21) 0.693
GRO-α (CXCL1) Chemokine 79.68 (62.17–106.42) 94.07 (75.45–136.63) 71.68 (59.64–108.71) 0.165
MCP-3 Chemokine 1.12 (1.12–1.81) 1.12 (1.12–1.12) 1.12 (1.12–1.12) 0.756
M-CSF Trophic factor 17.63 (15.53–20.24) 15.52(13.59–18.61) 14.07 (12.79–16.33) 0.091
MIF Trophic factor 341.60 (300.95–648.75) 533.18 (332.02–713.98) 422.92 (294.96–757.67) 0.735
TRAIL Chemokine 27.57 (20.71–41.82) 37.00 (28.74–49.13) 41.81 (24.69–52.82) 0.240
PDGF bb Trophic factor 6089.32 (4607.95–7902.88) 5245.34 (3467.16–7184.15) 4160.39 (3228.53–6158.09) 0.023
IL-2Ra Cytokine 32.39 (21.78–48.15) 28.74 (24.66–45.06) 29.92 (20.64–38.31) 0.348
IL-1ra Cytokine 206.06 (151.70–237.38) 151.69 (115.12–214.33) 124.59 (106.68–173.53) 0.041
HuLIF Trophic factor 13.36 (12.40–14.59) 12.40 (10.97–13.85) 12.40 (10.50–13.73) 0.495
HGF Trophic factor 590.86 (522.16–665.50) 446.23 (340.90–525.66) 390.50 (289.36–453.85) 0.004
FGF basic Trophic factor 5.24 (1.96–10.01) 1.96 (1.96–5.63) 1.96 (1.96–1.96) 0.022
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a chemoattractant for CD4+ T lymphocytes, monocytes and eosinophils
and is mainly produced by T lymphocytes (Cruikshank et al., 2000);
further, CD4+ T-cell inﬁltration in the CNS correlates with increased IL-
16 levels in brain lesions in EAE (Skundric, 2015). The IL-16 con-
centration in sera from MS patients was increased compared with
healthy controls, and the IL-16 serum levels were signiﬁcantly reduced
after two years of IFN-β1a treatment (Nischwitz et al., 2014). In ac-
cordance with these previous ﬁndings, in our study, 21 months of na-
talizumab treatment demonstrated the same ability to induce the re-
duction in IL-16 concentration.
Recent studies have described the anti-inﬂammatory action of
CCL11 (Eotaxin) in a model of experimental autoimmune encephalitis,
where the increased concentration of this chemokine was associated
with milder disease phenotype, reduced antigenic speciﬁc response and
a preferential activation of the Th2 immune response (Adzemovic et al.,
2012; Tejera-Alhambra et al., 2015). Consistent with this ﬁnding, in our
study a signiﬁcant increase in the expression of Eotaxin was observed
during the treatment, suggesting that natalizumab might limit the im-
mune and inﬂammatory processes in MS patients.
Hepatocyte growth factor (HGF) is a pleiotropic protein that mod-
ulates immune cell functions and also plays an inhibitory role in the
progression of chronic inﬂammation (Adams et al., 1994). HGF has
been found to be increased in CNS diseases, including MS (Tsuboi et al.,
2002), but some other studies have found decreased HGF CSF levels in
patients with MS or unaltered levels of plasmatic HGF between MS
patients and healthy controls(Benkhoucha et al., 2010; Muller et al.,
2012). This discrepancy might be attributed to the fact that there is a
compartmentalization of the HGF, produced by the lymphocytes pre-
sent in the CSF, and not in the serum. In line with these last surveys, in
our study a signiﬁcant decrease of HGF concentration in serum of MS
patients treated with natalizumab was observed and this ﬁnding may be
associated with the beneﬁcial eﬀect of natalizumab.
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Fig. 1. Serum levels of the seven proteins that were signiﬁcantly increased (Eotaxin) or decreased (IL-1ra, IL-7, IL-10, PDGFbb, IL-16 and HGF) during the 21 months of natalizumab
treatment. The concentrations were measured before starting the treatment (T0), after 12 months (T12) and after 21 months (T21) and are provided as log pg/mL. Data are presented as
median and interquartile ranges.
p: 0,024 p: 0,003 
Fig. 2. Th2/Th1 ratios were signiﬁcantly
changed during the time of treatment.
Comparative Th2/Th1 ratios considering anti-
inﬂammatory IL-10 cytokine and pro-in-
ﬂammatory cytokine IFN-γ (A) or TNF-α (B).
Box and whiskers plots showing median and
interquartile ranges are presented.
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Finally, we showed that IL-1ra levels also decreased in the sera of
patients during the natalizumab treatment. It has been previously stated
that IL-1ra may have a downregulating potential in the disease course
of MS, and elevated serum levels in active as well as in stable disease
stages have been found compared to controls (Heesen et al., 2000).
However, data regarding the role of IL1ra are very poor in literature
and it is hard to deﬁne the signiﬁcance of these results.
Besides the eﬀect of natalizumab treatment on the concentration of
the circulating cytokines/chemokines, we veriﬁed whether the mono-
clonal antibody aﬀected the replication of JCPyV and/or the IgG re-
sponse to the virus. However, we could not observe any signiﬁcant
change in the viruria of the patients during the course of treatment,
neither in the rate of antibodies directed against JCPyV. This is contrast
with some previous published data, that showed increase in JCPyV
viruria, seropositivity rate and in the antibodies index in diﬀerent co-
horts of MS patients treated with natalizumab for at least 12 months
(Delbue et al., 2015; Outteryck et al., 2014; Raﬀel et al., 2015). We
attributed the discrepancy of these ﬁndings to the small sample size
analyzed in our study.
5. Conclusions
Long-term treatment of natalizumab was associated with reduced
levels of some pro-inﬂammatory cytokines/chemokines, such as IL-7,
IL-16, and with increased levels of Eotaxin. These ﬁndings may be re-
lated to the beneﬁcial eﬀects associated with natalizumab. However,
the treatment did not modify regulatory T cell function or cause a re-
levant switch in the Th2/Th1 balance, suggesting that natalizumab has
marginal impact on the systemic immunity.
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Aim: Merkel cell polyomavirus (MCPyV) is the etiological agent of Merkel cell carcinoma. Its genome has
been detected in anatomic districts from healthy and ill subjects. Data regarding the MCPyV DNAemia
in neurological patients are lacking. Materials & methods: Blood was obtained from 129 neurological
patients and 181 controls (HIV positive or negative). Real-time polymerase chain reaction (Q-PCR) was
conducted to quantify MCPyV loads in blood specimens. Results: MCPyV DNA was detected in 17.1% of
cases and 11.0% of controls in <1% of cells. No association between MCPyV DNA presence and HIV status
was observed. Conclusion: Blood cells may be a reservoir for MCPyV. The presence of MCPyV genome in
blood of healthy subjects might be relevant for transfusion medicine.
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Merkel cell polyomavirus (MCPyV) was first identified in 2008 in Merkel cell carcinoma (MCC), a rare but
aggressive neuroendocrine skin tumor with approximately 80% of cases positive for MCPyV genome [1]. MCPyV
has a circular, double-stranded DNA genome of 5387 bp with a genomic organization largely similar to other
polyomaviruses. The genome is composed of a noncoding control region, containing the bidirectional origin
of replication, separating the early functional and the late structural regions. As for the other members of the
Polymaviridae family, the primary infection is thought to occur during early childhood, which is generally asymp-
tomatic and is followed by the latent establishment of the virus in the host [2]. Serological tests revealed that MCPyV
seroprevalence in the general population ranges from 46 to 88% [2–4]. The epithelial MCPyV tropism supports
the theory that the virus could be part of the normal microflora of the human skin [5]. Although MCPyV DNA
has been mainly detected in skin tissues, some scientific reports showed the presence of viral sequences also in
normal tissues from other anatomic districts including the respiratory tract (nasal swabs and saliva), the oral cavity
(tonsil biopsies), the lymphoid tissue, the GI tract (gallbladder, appendix, liver, lung and intestinal tissues), the
genital tract (vulva and penis) and the urinary tract, with a relatively low viral load compared with that of the
skin samples [1,3–4,6–16]. Recently, at least three independent metagenomics analyses, conducted on several samples,
identified sequences belonging to MCPyV in blood products eligible for transfusion and in blood from patients
affected with different diseases [17–20]. This finding supports the hypothesis that blood cells might be a reservoir for
MCPyV [21], also suggesting other possible viral tropisms and different alternative routes of transmission. However,
data regarding the MCPyV DNAemia in neurological patients are still lacking.
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Table 1. Sequences of primers and probes used for the quantitative real-time PCR assays to detect and quantify
Merkel cell polyomavirus genome and the -globin gene.
Target Region Primer/probe Position Sequence
Chromosome 11 -globin -globin-354F 62190–62209† 5′-GTGCACCTGACTCCTGAGGAG-3′
-globin-455R 62271–62290† 5′- CCTTGATACCAACCTGCCCAG-3′
-globin-402T Probe 62238–62263† 5′JOE-AAGGTGAACGTGGATGAAGTTGGTGG-TAMRA 3′
MCPyV VP1 gene MCPyV Forward 4053–4072‡ 5′-TGCCTCCCACATCTGCAAT-3′
MCPyV Reverse 4090–4112‡ 5′-GTGTCTCTGCCAATGCTAAATGA-3′
MCPyV Probe 4074–4089‡ 5′-FAM-TGTCACAGGTAATATC-MGB-3′
†The nucleotide positions are referred to strain U01317.
‡The nucleotide positions are referred to strain EU375803.
MCPyV: Merkel cell polyomavirus.
Data taken from [6,23].
Materials & methods
Subject enrollment & sample collection
Peripheral blood was collected from 129 patients affected with different neurological diseases, either HIV positive
or negative, who have been divided into two groups. The first group of HIV negative patients included 71 pa-
tients affected with relapsing-remitting multiple sclerosis (RR-MS), including 45 subjects undergoing natalizumab
treatment and 26 patients undergoing IFN-β treatment. The second group of HIV positive patients included 41
patients affected with leukoencephalopathies, both JC virus related (progressive multifocal leukoencephalopathy
[PML]) and JC virus negative leukoencephalopathies (not determined leukoencephalopathy [NDLE]), and 17
patients with other neurological diseases. The control group was composed of 181 subjects, including 99 HIV
negative healthy controls (HC) and 82 HIV positive patients without any neurological signs (NND). Additionally,
16 paraffin-embedded tissues from MCC patients were obtained from the pathology archive of the Ospedale
Maggiore della Carita`, Novara, Italy, and included in the study as positive controls. After routine blood sample
collection at the Neurologico Mondino Hospital and at the Policlinico San Matteo, Pavia, part of the samples was
delivered to the Department of Biomedical, Surgical and Dental Sciences, Milan and stored at -80◦C until use.
This study was approved by the local Ethics Committee and all patients signed a free and informed consent form
at the time of sample collection.
DNA extraction from blood & parafin-embedded tumor tissues
Viral DNA was isolated from 0.2 ml of blood and from the paraffin-embedded tissues using the commercial
kits QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and Qiagen DNeasy FFPE Kit (Qiagen), re-
spectively, in accordance with the manufacturer’s instructions. The purity and quantity of DNA were assessed by
spectrophotometric analysis according to the 260/280 nm ratio absorbance method.
Quantitative real-time PCR assay
Quantitative real-time PCR assay (Q-PCR) was performed using the Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems, CA, USA) with specific primers and TaqMan probe technology targeting the Viral
Protein 1 (VP1) sequence of the MCPyV, as previously described (Table 1) [6]. Q-PCR assay and thermal cycle
conditions were performed in accordance with a previously published protocol, and the standard curves were
constructed using a tenfold dilution series of a plasmid containing the VP1 gene of MCPyV (dilution range:
108–100 copies/µl) [22]. The limit of detection was 10 copies/µl. To determine the percentage of infected cells, a
concomitant Q-PCR assay targeting the β-globin gene was performed on the same samples. The β-globin gene was
amplified using the primer set and the thermal cycles previously published [23], as reported in Table 1. Negative and
positive controls were included in each run. Each sample, standard and control, was tested in duplicate. Results
were analyzed by the absolute quantification method and the data were expressed as MCPyV copies per ml/mg
of blood/tissue and reported as percentage of infected cells that was calculated as follows: ([viral copies/ml or
mg]/[beta-globin copies/2/ml or mg])*100.
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Table 2. Sequence of primers for the nested/semi-nested PCRs used for the ampliication of two fragments of the
LTAg and one fragment of the VP1 genes.
Region Outer/inner PCR Primers Position† Sequence Fragment length Ref.
LTAg Outer LT3FE 571–590 5′-TTGTCTCGCCAGCATTGTAG-3′ 280 bp [1]
LT3RE 860–879 5′-ATATAGGGGCCTCGTCAACC-3′
Inner LT3FI 741–760 5′-ATCTGCACCTTTTCTAGACTCC-3′ 151 bp
LT3RE 860–879 5′-ATATAGGGGCCTCGTCAACC-3′
LTAg Outer Tag FwE 1716–1736 5′-GCCTGTGAATTAGGATGTATTTT-3′ 477 bp [12]
Tag RevE 2210–2198 5′-TGGAAATGACCAGGACAGAAATG-3′
Inner Tag FwI 2010–2033 5′-GCCCATTATCTAGACTTTGCAAA-3′ 183 bp
Tag RevI 2192–2173 5′-TAGCCAAAAGGAGGTTAGA-3′
VP1 Outer VP1 FwE 3174–3194 5′-GGCTTTCTTTTTGAGAGGCCT-3′ 440 bp [12]
VP1 RevE 3613–3592 5′-TCCTTTGCATAGAGGGCCCACT -3′
Inner VP1 FwI 3276–3297 5’-TTGGGTAAACAGTTTTCTCCTG-3′ 240 bp
VP1 RevI 3515–3493 5′-AGTAACATTAAAATATCTAGGCA-3′
†The nucleotide positions are referred to strain EU375803.
Molecular characterization
The strains amplified from the MCC paraffin-embedded tissues were subjected to three different PCRs, for the
amplification of two fragments belonging to the LTAg and one to the VP1 regions. The first set of primers, the outer
TAg FwE and TAg RvE [12], and the inner TAg FwI and Tag RvI, amplify a 183-bp fragment. The second MCPyV
LTAg semi-nested PCR was conducted using the outer primer set LT3FE and LT3RE [1], and the semi-inner pair
set, LT3FI and LT3RE, which amplify a fragment of 151 bp. The analysis of the VP1 region was done using a
primer set previously described [12], VP1 FwE and VP1 RevE (outer) and VP1 FwI and VP1 RevI (inner), which
amplify a 240-bp fragment (Table 2). Each PCR fragment was sent to an external facility for the direct sequencing
of both viral strands (Eurofins Genomics, Vimodrone, Italy). Sequence homology searches were performed using
a nucleotide BLAST search, database search set ‘others’, from NCBI site , and, as reference sequence, the MCPyV
strain MCC350 (GenBank accession number EU375803) [24].
Statistical analysis
The χ2 test and the Fisher exact test were used to evaluate the significance of the association between MCPyV
infection and neurological disease, and specifically MCPyV infection and MS. Logistic regression was used to
evaluate the association between infection, neurological disorders and HIV positivity. p < 0.05 was considered
significant.
Results
Patient demographic characteristics
Overall, 129 patients and 181 controls were included in this study. Demographic of patients and control subjects
is summarized in Table 3.
Merkel cell polyomavirus prevalence in blood samples
MCPyV prevalence and the related mean viral load in the different groups of study are summarized in Table 4.
Prevalence in the case and control groups was 17.1% (22/129) and 11.0% (20/181), respectively. Taking into
account the subgroups of patients and controls, among the HIV negative neurological patients, overall positivity
was 12 out of 71 (16.9%), distributed as follows: 11 out of 45 (24.4%) subjects resulted positive in the RR-MS
group of patients undergoing natalizumab treatment, whereas 1 out of 26 (3.8%) subjects was MCPyV positive in
the RR-MS group of patients undergoing IFN-β therapy. Regarding the HIV positive group of study, an overall
positivity of 10 out of 58 (1.7%) subjects was reported, distributed as follows: 2 out of 17 (11.8%) subjects resulted
positive in the PML group, 4 out of 24 (16.7%), and 4 out of 17 (23.5%) subjects were MCPyV DNA positive in
the NDLE, and other neurological diseases groups, respectively. Concerning the control groups, the positive results
were distributed as follows: 14 out of 82 (17.1%) among the HIV positive NND patients, and 6 out of 99 (6.1%)
among the HIV negative subjects.
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Table 3. Demographic and clinical data of the enrolled patients and controls.
Groups n Female (%) Mean age ± range HIV status
Neurological patients
Relapsing-remitting multiple sclerosis (natalizumab treated) 45 34 (26.4) 40.2 ± 10.5 -
IFN- treated 26 17 (13.2) 41.9 ± 11.0 -
Progressive multifocal leukoencephalopathy 17 5 (3.9) 41.0 ± 10.2 +
Nondetermined leukoencephalopathy 24 9 (6.9) 44.5 ± 7.5 +
Other neurological diseases 17 6 (4.7) 46.5 ± 8.6 +
Total 129 71 (55.0) 42.3 ± 13.0
Controls
Healthy controls 99 53 (53.5) 59.0 ± 19.3 -
Non-neurological diseases HIV+ 82 24 (29.3) 44.5 ± 7.5 +
Total 181 77 (42.5) 51.8 ± 12
Table 4. Prevalence and mean viral load of Merkel cell polyomavirus in the blood of the enrolled patients and
controls.
Patients Treatment MCPyV+/Tot (%) Mean viral load copies/ml
(range)
Infected cells
Neurological patients
Natalizumab treated 11/45 (24.4)†‡ 1.5 × 105
(1.2 × 103–1.4 × 106)
0.005
Relapsing remitting MS
IFN- treated 1/26 (3.8)†‡ 1.3 × 105 0.003
Progressive multifocal leukoencephalopathy 2/17 (11.8) 6.3 × 103
(1.8 × 102–1.2 × 104)
0.041
Nondetermined leukoencephalopathy 4/24 (16.7) 8.2 × 105
(7.4 × 10–2.6 × 106)
0.982
Other neurological diseases 4/17 (23.5) 1.3 × 104
(4.4 × 10–5.0 × 104)
0.064
Total 22/129 (17.1) 2.2 × 105
(7.4 × 10–2.6 × 106)
0.219
Controls
Healthy controls 6/99 (6.1)‡ 1.5 × 105
(1.2 × 103–1.4 × 106)
0.04
Non-neurological diseases HIV+ 14/82 (17.1) 2.3 × 104
(4.9 × 10–1.6 × 106)
0.14
Total 20/181 (11) 8.6 × 104
(4.9 × 10–1.6 × 106)
0.09
†p  0.05.
‡p  0.005.
MS: Multiple sclerosis.
Considering HIV negative patients and comparing MS patients with HC, the percentages of infections were
16.9% (12/71) and 6.1% (6/99), respectively, with an odds ratio of 0.30 (Fisher exact test, p = 0.02).
The association between HIV infection and virus positivity was not statistically significant (p = 0.09) even after
adjusting for the presence of neurological disorders (p = 0.09).
There was no evidence of differences in the viral load distributions between cases and controls, and the mean
percentage of infected cell values in the blood samples of each group resulted lower than 1% without statistically
significant differences between the groups, according to the type of pathology.
Merkel cell polyomavirus prevalence in parafin-embedded tissues
The prevalence in the positive control group of paraffin-embedded MCC tissue samples revealed MCPyV positivity
of 10 out of 16 (62.5%; p < 0.0001; compared with both the case and control groups). Furthermore, viral load
analysis revealed a mean viral load of 5.3 × 103 copies/mg (range: 2.6 × 100–4.1 × 104 copies/mg) with a mean
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percentage of infected cells of 57.5%. The amplified and sequenced strains were all defined as MC3350 (data not
shown).
Discussion
In the present study, we detected MCPyV DNA in the blood of both neurological patients and controls, without
significant differences in the frequency. However, a significant higher frequency was observed in RR-MS patients
compared with HC, and among the MS patients, MCPyV was significantly more present in RR-MS patients treated
with natalizumab than in RR-MS patients undergoing IFN-β treatment.
To date, no other reports have been published with regard to the presence of MCPyV genome in MS patients.
Here, we showed that 24.4% of the RR-MS patients treated with natalizumab had MCPyV in the blood cells. This
result is comparable with the presence of the human polyomavirus JC (JCPyV), whose viremia detection varies
between 0 and 34.7% in different natalizumab treated cohort of MS patients [2,25–33].
The results of our study indicated an almost null presence of MCPyV DNA in the blood of the RR-MS patients
treated with IFN-β, suggesting that IFN-β could have an antiviral effect on MCPyV, as already observed for
JCPyV [34–36]. To this regard, it has been shown that Type I IFN-β is able to reduce the large T-antigen expression
and this may explain its antiviral effect [37].
Although this is the first report concerning the MCPyV DNAemia in neurological disorders, some other
pathologies have been previously studied and MCPyV has been shown to be present in the blood cells of 9.9%
of the studied patients with respiratory, cardiovascular or other diseases, such as hypertension, cancer, depression,
dementia and rheumatic disease [38]. Moreover, based on the frequent association between human polyomaviruses
reactivation after an immune impairment and the development of pathologies, more attention has been given
to the possible role of MCPyV in the diseases of the immunocompromised host. A recent study showed the
presence of MCPyV DNA in the blood of 17 out of 167 prospectively recruited adult patients undergoing kidney
transplantation, but with a very low mean viral load [39]. Furthermore, in a study conducted in the USA in 2012,
MCPyV genome was found in the blood of 26% patients with uncharacterized chronic lymphocytic leukemia [40].
To this regard, some reports showed that patients with MCC have an increased risk of developing leukemia and/or
lymphoma, proposing a possible MCPyV role in the pathogenesis of those diseases [40–42]. This hypothesis was
supported by a recent report by Song and Gyarmati, who were able to amplify the entire genomic sequence of
MCPyV in the blood of a patient with acute myeloid leukemia [43].
Interestingly, our results did not indicate any association among the presence of MCPyV DNA in the blood and
the HIV infection status of the enrolled patients and controls. Accordingly, Dang and colleagues did not find any
associations between MCPyV detection in blood and immunosuppression due to HIV [44]. This is in contrast with
the observation that MCC occurs more frequently in HIV positive patients than in immunocompetent hosts [45–49].
Fukumoto and colleagues also reported a significantly higher prevalence of MCPyV DNA in the sera from HIV
positive patients than from HIV negative patients, affected with different diseases [50]. However, they observed no
differences in the MCPyV load, as we did. On the other hand, and supporting our results, a recent paper reported
no differences in the prevalence rate of MCPyV-DNA in the blood of HIV/AIDS, non-AIDS HIV infected and
uninfected controls (from 14 to 17%) [51].
Even if the mean viral load was more than 100-fold higher in NDLE patients than in PML patients in our study
as expected, the presence of MCPyV genome in all groups of subjects was limited to less than 1% of blood cells,
while the virus was shown to infect at least 50% of MCC cells. This finding supports the hypothesis that the blood
might represent a reservoir for the virus in its latent state.
Additionally, it is worthy to underline the importance of the presence of the MCPyV genome in the blood of
HC. To this regard, Mustafa and colleagues conducted the whole-genome sequencing analysis of 8240 blood DNA
samples from healthy subjects without any ascertained infectious disease. The analysis showed the presence of 94
different viruses, including sequences from human DNA viruses, proviruses and RNA viruses in 42% of the study
participants, among which 49 individuals resulted positive for MCPyV sequences [18,19]. These data confirmed
previously results obtained in another scientific work conducted on 60 buffy coats, obtained from healthy blood
donors recruited in Italy. The results indicated that 13 out of 60 samples were positive for MCPyV LTAg sequences
with low viral DNA load [19]. However, to give a complete scenario, it is also important to note that Dworkin and
colleagues did not detect MCPyV genome in any of the tested normal blood samples [52].
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Conclusion & future perspective
It is clear that MCPyV is able to remain in a latent state, even at very low concentration in the blood cells of the
host. This is an important issue considering MCPyV can reactivate and is the cause of a severe disease such as
MCC. Additionally, and not less important, the presence of viruses in blood products can be relevant for transfusion
medicine and it would be worthy to discuss about the opportunity and/or the urgency to add MCPyV to the list
of viruses that could be potentially transmitted via blood products [18].
Summary points
 Merkel cell polyomavirus (MCPyV) was irst identiied in the Merkel cell carcinoma cells.
 MCPyV is a ubiquitous virus, which establishes lifelong latency and can reactivate in immunosuppressed
individuals.
 MCPyV genome has been found in the blood cells from healthy subjects and patients affected with different
diseases. However, nothing is known about the MCPyV DNA presence in the blood from patients affected with
neurological diseases.
Methods
 Peripheral blood was collected from 129 patients with neurological diseases: 71 multiple sclerosis (MS) patients
(treated with natalizumab or IFN-β), 41 HIV positive patients with leukoencephalopathies and 17 patients with
other neurological diseases. Control group was composed by 181 subjects: 99 healthy subjects and 82 HIV positive
patients without any neurological symptoms.
 MCPyV DNAemia was evaluated by means of speciic real time polymerase chain reaction (Q-PCR).
 The chi square test and the Fisher exact test were used to evaluate the signiicance of the association between
MCPyV infection and neurological disease, and MCPyV infection and MS. Logistic regression was used to evaluate
the association between infection, neurological disorders and HIV positivity.
Results
 MCPyV DNA was detected in the blood of 17.1% of cases and 11.0% of controls.
 MCPyV DNA was detected in very low percentages of cells (<1%) both in the cases and in the controls.
 Higher frequency of MCPyV DNA was found in the blood from relapsing-remitting MS (RR-MS) patients, treated
with natalizumab compared with RR-MS patients treated with IFN-β and healthy controls.
Discussion
 This was the irst report regarding the presence of MCPyV DNA in blood from patients with neurological diseases.
 The prevalence of MCPyV DNAemia was similar in cases and controls, and HIV infection was not associated with
the presence of MCPyV genome.
 The higher presence of MCPyV genome in RR-MS patients treated with natalizumab than in RR-MS patients
treated with IFN-β could be due to a strong antiviral effect of the IFN-β.
 Blood cells could be a reservoir for MCPyV, which may be able to reactivate during immunosuppression of the
host.
 The presence of MCPyV DNA in blood from healthy controls can be relevant for transfusion medicine.
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Abstract 
Prostate cancer (PCa) is one of the most common male neoplasms in the Western world. 
Various risk factors exist that may lead to carcinogenesis, including exposure to infectious 
agents such as the polyomavirus BK (BKPyV), which infects the human renourinary tract, 
establishes latency, and encodes oncoproteins.  
Previous studies have suggested that BKPyV plays a role in PCa pathogenesis. However, the 
unspecific tropism of BKPyV and the lack of in vitro models of BKPyV-infected prostate 
cells cast doubt on this hypothesis.  
The aim of the present study was to determine whether BKPyV could a) infect normal and/or 
tumoral epithelial prostate cells, and b) affect their phenotype. Normal epithelial prostate 
RWPE-1 cells and PCa PC-3 cells were infected with BKPyV for 21 days. Cell proliferation, 
cytokine production, adhesion, invasion ability, and epithelial-to-mesenchymal transition 
(EMT) markers were analyzed. 
Our results show that a) RWPE-1 and PC-3 cells are both infectable with BKPyV, b) cell 
proliferation and TNF-α production were increased in BKPyV -infected RWPE-1, but not in  
PC-3 cells, c) adhesion to matrigel and invasion abilities were elevated in BKPyV-infected 
RWPE-1 cells, d) loss of E-cadherin and expression of vimentin occurred in both uninfected 
and infected RWPE-1 cells. In conclusion, BKPyV may change some features of the normal 
prostate cells, but is not needed for maintaining the transformed phenotype in the PCa cells 
The fact that RWPE-1 cells exhibit some phenotype modifications related to EMT represents 
a limit of this in vitro model.  
 
 
Key words: Prostate Cancer, Polyomavirus, in vitro model, cytokine production 
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Introduction 
Prostate cancer (PCa) is the most common malignant neoplasm in men and the second 
leading cause of cancer-related death in the Western world (NCI-NIH, 2018). In addition to 
several risk factors that play a role in PCa development, infectious agents such as the human 
polyomavirus BK (BKPyV) should be considered in PCa studies. BKPyV has been 
categorized by the International Agency for Research on Cancer as “possibly” carcinogenic 
to humans due to evidence of carcinogenic activity in vitro in cell lines and in vivo in animals 
(Bouvard et al., 2012). Additionally, the potential association between BKPyV and PCa is 
supported by previous studies, indicating that BKPyV infection is significantly more 
prevalent in cancer tissues than in control tissues, and that there is a significant association 
between viral expression and cancer (Delbue et al., 2014). Unfortunately, the unspecific 
tropism of BKPyV and the lack of in vitro models of BKPyV infection in prostate cells cast 
doubt on this hypothesis.  
The “phenotypic switch” that changes the phenotype of a cell from epithelial-to-
mesenchymal, also referred to as the epithelial-to-mesenchymal transition (EMT) process, 
plays a pivotal role in PCa progression, because it causes tumor cells to become invasive and 
able to metastasize to distant organs. The main characteristics of the EMT phenotype are loss 
of cell-cell adhesion and epithelial polarity markers (due to downregulation of E-cadherin), 
cytoskeleton reorganization (via expression of vimentin and α-smooth muscle actin), 
abnormal motile properties, and secretion of matrix metalloproteinases (MMPs) (Thiery, 
2002). 
The main goal of the present study was to determine whether BKPyV could infect normal 
and/or neoplastic prostate epithelial cells and, if so, whether this could affect cell 
morphology, proliferation, and adhesive properties, focusing also on EMT markers. For this 
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purpose, we used the normal human prostate epithelial cell line RWPE-1 and the human  PCa 
cell line PC-3. 
 
Materials and methods 
Cell cultures 
The RWPE-1 (ATCC® CRL-11609) cell line was established from the epithelial cells of the 
peripheral zone of a normal adult human prostate, transfected with a single copy of human 
papillomavirus 18 (HPV-18). RWPE-1 cells were grown in a keratinocyte serum-free 
medium (K-SFM; GIBCO/Invitrogen, Karlsruhe, Germany) supplemented with 50 µg/mL 
recombinant human epidermal growth factor (rhEGF; GIBCO/Invitrogen, Karlsruhe, 
Germany), 5 ng/mL bovine pituitary extract (BPE; GIBCO/Invitrogen, Karlsruhe, Germany), 
and antibiotics (2.5 µg/mL Fungizone™; GIBCO/Invitrogen, Karlsruhe, Germany) (50 U/mL 
penicillin; 50 µg/mL streptomycin; Euroclone, Italy). The human PCa cell line PC-3 
(ATCC® CRL-1435) was derived from the grade IV prostate adenocarcinoma metastasis of a 
62-year-old Caucasian patient. PC-3 cells were grown and subcultured in nutrient mixture 
Ham’s F-12 Coon’s modification medium with L-glutamine (Sigma-Aldrich, Germany) 
containing 10% v/v fetal bovine serum and antibiotics (50 U/mL penicillin; 50µg/mL 
streptomycin; Euroclone, Italy). All cells were maintained in an incubator at 37 °C in a 5% 
CO2 humidified atmosphere.  
BKPyV infection 
Cells were infected using 108 virions (4*106 virus copies/mL) of BKPyV archetype (WW) 
strain stock, that was purchased at ATCC® (VR-837). The day before infection, 2*106 cells 
were plated in a T75 flask. On day 0, the cells (which reached 70% confluence) were washed 
twice with Dulbecco’s phosphate-buffered saline w/o calcium and magnesium (DPBS; 
Euroclone, Italy) and then the virus stock, diluted with specific serum-free culture medium, 
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was added to the flask. The cells were held at 37 °C for 90 min. Then, the inoculum was 
removed, the cells were washed with DPBS in order to eliminate the unbound virus, and the 
complete medium was added. The uninfected control was created following the same 
procedure as for the infected cells but without the addition of the virus. 
Infected and uninfected cells were continuously cultured with complete medium and were 
split every three days up to 21 days. For each splitting, aliquots of cells and cell culture 
supernatants were collected. Virions were precipitated from the culture medium using PEG-it 
Virus Precipitation Solution (PEG) (System Biosciences, USA) and then treated with DNase 
I; briefly, one part cold PEG (4 °C) was added to every four parts culture medium, 
refrigerated overnight, then processed according to the manufacturer’s protocol. Supernatants 
were diluted 1:1 with nuclease-free water and treated with 5 U DNase I (5 U/µl) (AppliChem, 
Germany) or mock-treated with water. After 1 h at 37 °C, the enzyme was heat- inactivated at 
99 °C for 10 min (Kantola et al., 2009).  
BKPyV DNA isolation and quantitative real-time PCR 
Viral DNA was isolated from the encapsidated virions and from the cell pellet using a 
Nucleospin RNA kit (Macherey-Nagel, Germany) and a QIAamp DNA blood mini kit 
(Qiagen, USA) according to the manufacturer’s instructions. Titration and evaluation of 
extracellular and intracellular viral loads were carried out by BKPyV-specific quantitative 
real-time PCR (Q-PCR). 
BKPyV Q-PCR assays were performed using a TaqMan chemistry with an Applied 
Biosystems 7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA), targeting the 
highly-conserved VP1 region and following a protocol previously described by Delbue and 
colleagues (Kantola et al., 2009). A standard curve for quantification of the BKPyV viral load 
was obtained after serial dilution of the plasmid pBKPyV Dunlop with a dilution range 
between 100 and 108 plasmid copies/µL. Negative controls were included in each run and for 
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each sample. Standards and controls were tested in triplicate. Data are expressed as viral 
copies/mL. 
Cell proliferation assay 
The viability of infected and uninfected cells was measured by 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) assay. BKPyV-infected and uninfected cells were 
seeded in 96-well plates (5*104 cells per well) and cultured in complete medium at 37 °C and 
5% CO2 for 24 hours, 48 hours, 72 hours, and 6 days. At each point in time, cells were 
washed with DPBS, and after adding 100 µL MTT (Sigma-Aldrich, Germany), were left for 3 
hours at 37 °C in the dark. Following incubation, the plate was centrifuged at 1200 rpm for 
10 min and then the medium was removed. To dissolve formazan product crystals, dimethyl 
sulfoxide (DMSO; Sigma-Aldrich, Germany) was added to each well and the plate was 
shaken for 10 min in the dark. Absorbance was measured using a BioTek Synergy™ 4 
Hybrid Microplate Reader (Biotek, USA) at 550 nm. The background, read at 650 nm, was 
removed. Three replicates were made for each group. Cell viability was calculated as follows:  
 
Cell viability %            =           (Absorbance of sample - Absorbance of blank)     × 100 
                                                            Absorbance of negative control 
 
Cytokine, chemokine, and growth factor analysis 
Quantification of 48 different cytokines, chemokines, and growth factors (pro-human 
cytokine 27-Plex M50-0KCAF0Y and 21-Plex MF0-005KMII, Bio-Rad, Hercules, CA) was 
performed on the culture media of both BKPyV-infected and uninfected RWPE-1 and PC-3 
cell lines when cells were split, by magnetic bead-based multiplex immunoassay (Bio-Plex®) 
(BIO-RAD Laboratories, Milano, Italy), following the manufacturer’s instructions. 
Specifically, we determined the presence and concentration of IL 1α-β-ra-2-2Ra-3-4-5-6-7-8-
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9-10-12p40 and p70-13-15-16-17-18, eotaxin, basic FGF, G-CSF, GM-CSF, IFN-γ, IP10, 
MCP1-α, MCP1-β, PDGFBB, RANTES, TNF-α, VEGF, CTACK, GRO-α, HGF, IFN-α2, 
LIF, MCP-3, M-CSF, MIF, MIG, β-NGF, SCF, SCGF-β, SDF1-α, TNF-β, TRAIL, ICAM1, 
and VCAM1. For data acquisition and output, we used the Bio-Plex 200 reader and a digital 
processor. The Bio-Plex Manager® software presented data as median fluorescence intensity 
(MFI) and concentration (pg/mL) (BIO-RAD Laboratories, Milano, Italy), as described 
previously (Campisciano et al., 2018). 
Matrigel cell adhesion 
96-well plates were coated with 200 µL/cm2 Cultrex® Basement Membrane Extract without 
phenol red (BME, PathClear®), a soluble form of basement membrane whose major 
components include laminin, collagen IV, entactin, and heparan sulfate proteoglycan. The 
plates were incubated at 37 °C for 30 min to allow polymerization of the matrix and the wells 
were washed with 1% bovine serum albumin in DPBS to block unspecified cell adhesion. 
Subsequently, infected and uninfected RWPE-1 and PC-3 cells were seeded at 5*104 cells per 
well and cultured in their specific complete media at 37 °C and 5% CO2 for 60 min. A plastic 
plate was used as background control. To remove cells that did not adhere to the matrix, the 
wells were washed with specific cell-type media. The remaining adherent cells were fixed 
with 1% glutaraldehyde and counted microscopically. The mean cellular adhesion rate 
(adherent cells in coated wells - adherent cells in uncoated wells) was calculated from three 
different observation fields using a phase-contrast microscope. The invasive characteristics of 
both cell lines were evaluated at days 4, 8, 15, and 21 post-infection, and compared with 
those of uninfected cells. 
Immunofluorescence for EMT marker analysis 
RWPE-1 and PC-3 cells were cultured on 12-mm diameter round coverslips in 24-well 
culture plates. Cells were washed in DPBS, fixed in 4% paraformaldehyde in DPBS 
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containing 2% sucrose for 10 min at room temperature, post-fixed in 70% ethanol, and stored 
at -20 °C until use. Cells were then washed in DPBS three times and incubated for 1 hour at 
room temperature with the primary antibodies anti-E-cadherin (1:2500, Becton Dickinson), 
anti-N-cadherin (1:200, Santa Cruz), anti-vimentin (1:200, Novocastra), and anti-αSMA 
(1:400, Sigma-Aldrich). Secondary antibodies conjugated with Alexa 488 (1:500, Molecular 
Probes, Invitrogen) were applied in DPBS for 1 h at room temperature in the dark. Negative 
controls were incubated in the same way, omitting the primary antibody. Finally, cells on 
coverslips were incubated for 15 min with DAPI (1:100.000, Sigma-Aldrich) and mounted 
onto glass slides using Mowiol. The cells were photographed using a digital camera 
connected to a Nikon Eclipse microscope. 
SDS-zymography for invasive potential analysis 
Culture media were mixed 3:1 with sample buffer containing 10% SDS. Samples (10 µg total 
protein per sample) were run under non-reducing conditions without heat denaturation on 10% 
polyacrylamide gel (SDS-PAGE) co-polymerized with 1 mg/mL type I gelatin at 4 °C. After 
SDS-PAGE, the gels were washed twice in 2.5% Triton X-100 for 30 min each and incubated 
overnight in a substrate buffer at 37 °C (Tris-HCl 50 mM, CaCl2 5 mM, NaN3 0.02%, pH 7.5). 
After staining the gels with Coomassie Brilliant Blue R-250, MMP gelatinolytic activity was 
detected as clear bands on a blue background, quantified by densitometric scanning (UVBand, 
Eppendorf, Italy). 
Tissue inhibitor of metalloproteinase-2 real-time PCR 
Tissue inhibitor of metalloproteinase-2 (TIMP-2) gene expression was analyzed by real-time 
PCR. Total RNA was isolated by a modified version of the acid guanidinium thiocyanate-
phenol-chloroform method (Tri-Reagent, Sigma, Italy). 1 µg total RNA was reverse-
transcribed in 20 µL (final volume) reaction mix (Biorad, Segrate-Milan, Italy). TIMP-2 
mRNA levels were assessed and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
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used as an endogenous control to normalize differences in the amount of total RNA in each 
sample. The primer sequence was sense CCCTTCATTGACCTCAACTACATG, antisense 
TGGGATTTCCATTGATGACAAGC for GAPDH and sense 
TGGAAACGACATTTATGGCAACCC, antisense CTCCAACGTCCAGCGAGACC for 
TIMP-2. 
Amplification reactions were conducted in a 96-well plate in a final volume of 20 µL per 
well. Each well contained 10 µL 1X SYBR Green Supermix (BioRad, Italy), 2 µL template, 
and 300 pmol of each primer. Each sample was analyzed in triplicate in a Bioer LineGene 
9600. The cycle threshold was determined and gene expression levels relative to that of 
GAPDH were calculated. 
Electronic microscopy for morphological analysis 
RWPE-1 cells, grown at confluence, were harvested at 250 g for 5 min at room temperature. 
The culture medium was removed and replaced with a solution containing 2% freshly 
prepared paraformaldehyde and 2% glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 
7.4). After fixation for 2–4 h at 4 °C, cells were centrifuged and rinsed twice in cacodylate 
buffer for 20 min, post-fixed in 1% osmium tetroxide in the same buffer at 0 °C for 30 min, 
washed in distilled water, and en bloc stained with 2% aqueous uranyl acetate. After 
dehydration in a graded acetone series, samples were embedded in Epon-Araldite resin. 
Ultrathin sections (70–100 nm) were cut on a Leica Supernova ultramicrotome and stained 
with Reynolds’ lead citrate. Transmission electron microscopy was performed with a Zeiss 
EM10 electron microscope. 
Statistical analysis 
All experiments were performed three to six times. Statistical significance was assessed using 
the Wilcoxon-Mann-Whitney U test. Differences were considered statistically significant at p 
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< 0.05. Linear regression was performed for analyzing changes in cytokine concentration 
over time. 
Results 
BKPyV infection 
RWPE-1 and PC-3 cell lines were infected in vitro with a BKPyV archetype strain, and viral 
extracellular and intracellular DNA was quantified by specific Q-PCR at different time points 
postinfection. Both normal and cancerous epithelial prostate cell lines were found to be 
infectable with BKPyV, although a different time course of infection was observed in each 
cell line. Infection peaked on day 3 p.i. in RWPE-1 cells, with an extracellular viral load of 
4.0*106 copies/mL and an intracellular viral load of 2.3*106 copies/mL. Viral replication was 
observed until day 14 p.i. (culture medium: undetectable; cell pellet: 7.7*102 copies/mL) 
(Figure 1A). In the PC-3 cell line, infection peaked on day 10 p.i., and the virus remained 
productive over 21 days p.i. with a mean extracellular viral load of 6.9*105 copies/mL (range: 
8.7*103–2.6*106 copies/mL) and an intracellular viral load of 1.7*106 copies/mL (range: 
2.4*105–3.9*106 copies/mL) (Figure 1B). Uninfected RWPE-1 and PC-3 did not harbour 
BKPyV genome or other DNA virus genomes, besides HPV-18, used for the immortalization 
of the RWPE-1 (data not shown). 
BKPyV infection affects RWPE-1 cell proliferation 
To evaluate the effect of BKPyV infection on the growth rate of RWPE-1 and PC-3 cells, an 
MTT assay was performed on infected and uninfected cells. Infected cell viability was 
normalized to the viability of uninfected cells. Infected RWPE-1 cells showed a higher rate of 
proliferation compared to uninfected cells (range +25%/+58%, p < 0.05) (Figure 2A), 
whereas infected PC-3 cells displayed a significantly lower rate of proliferation than 
uninfected cells (range: -37%/-73%, p < 0.05) (Figure 2B). 
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BKPyV infection induces significant expression of inflammatory factors and activators in 
RWPE-1 cells 
A panel of 48 cytokines and chemokines in the culture supernatants of infected and 
uninfected RWPE-1 and PC-3 cells was analyzed at seven time points p.i (24 and 48 hours; 3, 
7, 12, 17, and 21 days). The concentration of three factors involved in the tumor 
inflammatory microenvironment (IL-18, TNF-α, and MCP1) increased significantly in the 
supernatant of RWPE-1 infected cells compared to mock-infected counterparts (linear trend 
estimation: R2 ≥ 0.6, p ≤ 0.04; Figure 3A, B, and C). In particular, the concentration of the 
proinflammatory cytokine TNF-α in the supernatant of the RWPE-1 infected cells showed a 
linear increase from 1.13 pg/mL at hour 24 to 6.86 pg/mL on day 21 (R2 = 0.9, p < 0.0001), 
which was much greater than the increase seen in uninfected cells (on average 1.58 ± 0.18 
pg/ml from 24 hours to 21 days). Among factors showing downregulation, the concentration 
of IL-3, a strong inducer of the active immune response, decreased significantly in the 
supernatant of infected RWPE-1 cells from 34.10 pg/ml at hour 24 to 6.58 pg/ml on day 21, 
unlike in their uninfected counterparts (4.77 to 48.05 pg/ml). The linear trend for IL-3 shows 
the significant impact of BKPyV infection on constitutive cytokine expression (R2 = 0.56, p < 
0.05) (Figure 3D). No significant linear trends were observed in the levels of 
cytokine/chemokine production between infected and uninfected PC-3 cells (table 1).   
Matrigel adhesion assay  
To investigate the effect of BKPyV infection on the invasive behavior of RWPE-1 and PC-3 
cells, both cell lines were seeded on BME, which mimics the extracellular matrix, and the 
binding rate of infected cells per mm2 was calculated. Results were normalized to the binding 
rate of uninfected cells. Both infected cell lines showed a higher binding rate compared to 
their mock treated counterparts. Specifically, the rate was between +17% and +1570% for 
RWPE-1 cells and between +9% and +811% for PC-3 cells (Figure 4, panels A and B).  
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EMT marker analysis  
EMT marker expression was assessed by immunofluorescence in both infected and 
uninfected RWPE-1 cells. At all time points, uninfected RWPE-1 cells exhibited low or 
undetectable levels of E-cadherin. Notably, immunoreactivity was observed mostly in the 
cytoplasm and not at cell boundaries, where functional adherens junctions are located in 
normal differentiated epithelial cells. Infected RWPE-1 cells showed a similar pattern of E-
cadherin expression. N-cadherin expression was almost undetectable, with scattered positive 
cells in both infected and uninfected RWPE-1 cells. Vimentin was expressed at similar levels 
in infected and uninfected RWPE-1 cells (Figure 5, panel A). 
To better understand the effect of BKPyV on normal epithelial cells and to further investigate 
its possible involvement in PCa oncogenesis, the expression of EMT markers was analyzed in 
PC-3 cells before and after BKPyV infection. As expected, E-cadherin was almost 
completely undetectable in both infected and uninfected PC-3 cells at all time points. N-
cadherin and vimentin expression were similarly expressed in control and BKPyV-infected 
PC-3 cells (Figure 5, panel B). 
Invasive potential 
To assess the invasive potential of infected and uninfected RWPE-1 and PC-3 cells, MMP-2 
and MMP-9 gelatinolytic activity in cell supernatants was assessed by SDS-zymography. 
Densitometric scanning of lytic bands on zymograms revealed that MMP-2 and MMP-9 were 
similarly expressed in uninfected and infected RWPE-1 cells up to day 3. However, at all 
subsequent time points, MMP-2 and MMP-9 were strongly induced in BKPyV-infected cells 
compared to uninfected cells (Figure 7, panel A and B). 
Densitometric analysis of lytic bands also showed that the activity of MMP-2 and MMP-9 in 
PC-3 cells were differently affected by BKPyV infection in a time-dependent manner that 
could not be properly defined (data not shown). To elucidate whether the invasive potential 
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of PC-3 cells was influenced by BKPyV infection, we analyzed the expression of TIMP-2, a 
natural inhibitor of MMP-2, and described MMP-2 and MMP-9 activity in relation to TIMP-2 
expression. The MMP-2:TIMP-2 ratio was strongly increased by BKPyV from day 3 to day 
14, and thereafter, was similar to that in control cells. A comparable pattern was observed in 
the MMP-9:TIMP-2 ratio (Figure 7, panel C). 
Morphological analysis by electron microscopy 
The morphology and ultrastructure of infected and uninfected RWPE-1 cells at different time 
points were analyzed by electron microscopy. For each pellet, 120 cells were photographed 
and evaluated to observe the presence of any viral particles. Both uninfected and infected 
cells showed similar morphologies (Figure 8, panel a) and contained a high number of viral 
particles (Figure 8, panel b). Surprisingly, viral particles were observed in both infected and 
uninfected RWPE-1 cells, although BKPyV DNA was undetectable by Q-PCR. 
Discussion 
BKPyV is a member of the Polyomaviridae family with very well-known in vitro oncogenic 
properties, mainly resulting from the production of large T antigen protein, which is able to 
induce cell transformation (Tognon et al., 2003). Based on serological and molecular studies, 
it has been suggested that BKPyV may be involved in the etiology and/or development of 
PCa (Delbue et al., 2014; Keller et al., 2015a). In addition, a study carried out on a large 
cohort of PCa patients revealed a statistically strong association between IgG response 
against LTag and the risk of PCa progression (Keller et al., 2015b). However, it remains 
uncertain whether BKPyV infection is the causative agent in PCa or is an epiphenomenon. 
Additionally, the lack of an in vitro model of BKPyV-infected epithelial prostate cells 
represents a major limit in this field.  
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Thus, in the present study, we infected prostate cells with BKPyV with the aim of 
establishing and characterizing an in vitro model to obtain innovative insight into the 
relationship between viral activity and possible phenotypic changes. 
We demonstrated for the first time that both the normal epithelial prostate cell line RWPE-1 
and the PCa cell line PC-3 are infectable with BKPyV. The outcomes of the infection vary 
between the two cell lines, being lost from RWPE-1 by day 14 p.i., but persisting in PC-3 up 
to three weeks p.i. The dramatic falling off of BKPyV copy number over two weeks in 
RWPE-1 lead to hypothesize that normal prostate cells are subjected to an abortive infection. 
On the contrary, PC-3 cells appear to maintain a steady state of BKPyV genome copies over 
time, so it is possible that a persistent infection was established. Unfortunately, the expression 
of either early or late viral proteins could not be assessed, and this represents a major limit of 
the study. Further study should be conducted in order to verify whether an abortive infection 
of the RWPE-1 cells could lead to viral DNA integration, protein expression limited to the T 
Antigens and possible cellular transformation.  
Additionally, our findings were not comparable with other studies, since all the previous 
experiments concerning BKPyV infection in vitro have been performed in human or monkey 
kidney cells, lung fibroblasts, or epithelial cells from salivary glands (Acott et al., 2006; 
Jeffers-Francis et al., 2015; Li et al., 2013). Despite its low level of replication, BKPyV 
seems to contribute to alter some of the properties of normal prostate cells, such as their rate 
of proliferation and the production of some factors which may be involved in malignant 
transformation. 
TNF-α is a pleiotropic cytokine that can induce cancer cell death, but may also favour cell 
proliferation under certain specific conditions (Tse et al., 2012). In addition, TNF-α 
orchestrates the expression of inflammatory cytokines involved in the development of 
castrate-resistant PCa, such as IL-6 (Nguyen et al., 2014). It was recently demonstrated that 
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the release of TNF-α in the microenvironment of PCa tumors leads to the expression of 
factors responsible for the progression of this malignancy (Banzola et al., 2018) . 
It has been shown that TNF-α produced by PCa cells is able to activate neutrophils and 
macrophages and induce the synthesis of other proinflammatory cytokines (Sharma et al., 
2014). In mice models with chemically-induced PCa, TNF-α has been shown to promote cell 
proliferation and survival (Galheigo et al., 2016). Interestingly, TNF-α had a strong growth-
stimulating effect on simian polyomavirus 40-transformed keratinocytes (Kobayashi et al., 
1999), and a similar effect on BKPyV-infected prostate cells can be hypothesized, upon 
synergic stimulation of proliferation with viral LTag.  
The combinatory upregulation of TNF-α, IL-18, and MPC-1 upon BKPyV infection might 
contribute to the promotion of prostatic cells toward a cancerous phenotype (Ito et al., 2015; 
Palma et al., 2013). In addition, the role of IL-18 as a potent inducer of IFN-γ, which is in 
turn the main inducer of IDO, suggests a relevant role of BKPyV in PCa development and 
progression (Feder-Mengus et al., 2008). Finally, the inhibition of IL-3 production should 
help BKPyV evade the host innate immune response (Broughton et al., 2012). 
On the contrary, PC-3 cells showed a decrease in their rate of proliferation, probably due to 
the cytopathic effect, and stable expression levels of TNF-α after BKPyV infection. Vaughan 
and colleagues also observed that TNF-α increased glycolysis, ATP production, and lactate 
export in RWPE-1 cells, but not in PC-3 cells (Vaughan et al., 2013). 
The binding of BKPyV-infected RWPE-1 and PC-3 cells to the extracellular matrix was 
evaluated in the present study, because direct interaction with the extracellular matrix may 
lead to transendothelial invasion. Higher adhesion to the Matrigel has been observed in 
BKPyV-infected cells relative to uninfected cells, even without a specific trend over time. 
Higher levels and activity of MMP-2 and MMP-9 in BKPyV-infected RWPE-1 showed that 
the virus elicited an invasive phenotype in normal cells. Increased expression of MMP-2 and, 
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consequently, strong invasive behavior of the cells has previously been described in a 
transgenic mouse model with polyomavirus-induced osteosarcoma (Velupillai et al., 2010). 
The same phenomenon was observed during the progression of mammary carcinomas in a 
polyomavirus middle T oncogene mouse model, where MMP-13 was strongly upregulated 
concurrently with the transition to invasive and metastatic carcinomas (Nielsen et al., 2008). 
Very recently, the induction of several MMPs has been described in an in vitro model of 
Merkel cell carcinoma induced by Merkel cell polyomavirus; the authors hypothesized that 
dysregulated MMP gene expression may contribute to virus-induced oncogenesis (Liu et al., 
2016). Both the enhanced cell adhesion to the extracellular matrix and the increased activity 
of MMP-2 and MMP-9 have been observed even after clearance of the BKPyV genome from 
the RWPE-1 cells. This finding may confirm the fact that the viral DNA is not retained in 
transformed cells and tumor samples, resembling the well-known hit-and-run model of viral 
tumorigenesis (Delbue et al., 2017). 
The increased levels and activity of MMPs induced by BKPyV in PC-3 cells suggests that the 
virus was effective in adding invasive potential to already established invasive properties. 
This effect is evident until 14 days p.i. and is lost thereafter, suggesting that its activity could 
play a major role in the early phases of oncogenesis, but is then stabilized. 
Although all the above evidence could reasonably lead to the hypothesis that BKPyV 
catalyses some changes in RWPE-1 cells, we observed an unexpected result regarding EMT 
markers and the EMT-related phenotype. Uninfected RWPE-1 cells are normal epithelial 
cells, but our data shows that they do not present a clear epithelial phenotype; E-cadherin 
downregulation and cytoplasmic localization was detected in most cells, and vimentin 
expression was observed in both control and BKPyV-infected cells, thus suggesting that 
uninfected cells underwent EMT. This finding was consistent with the morphological results 
in the same cells as described by Tamand colleagues. (Tam et al., 2017). To better understand 
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this unexpected result, we analyzed RWPE-1 cells with an electron microscope. Small viral 
particles were detected not only in BKPyV-infected cells, but also in normal, uninfected 
RWPE-1 prostate cells, although BKPyV viral DNA was undetectable by Q-PCR, suggesting 
that these viral particles were a result of HPV-18 used for RWPE-1 immortalization.  
It is likely that RWPE-1 cells, which have been immortalized with a defective HPV-18 
genome, are still able to produce viral capsid proteins (known as L1), which spontaneously 
self-assemble into a structure closely mimicking the natural surface of native papillomavirus 
virions (Buck et al., 2013). The concomitant presence of these pseudovirions and the 
observation of an EMT-related phenotype in uninfected RWPE-1 cells strongly suggests that 
RWPE-1 cells do not retain a normal epithelial morphology (Bello et al., 1997) and may not 
serve as a model of normal epithelial prostate cells, even if they are widely used in research 
(Deng et al., 2017; Souza et al., 2018). BKPyV-infected and uninfected RWPE-1 cells exhibit 
a similar EMT phenotype, suggesting that uninfected cells do not retain normal epithelial 
characteristics and thus their use as a model of normal epithelial prostate cells may be 
limited. However, under our experimental conditions, we were able to demonstrate that 
BKPyV infection induced increased gelatinolytic activity in RWPE-1 cells, allowing us to 
detect the effect of BKPyV in inducing the invasive properties of infected cells, consistent 
with their malignant transformation. Previous reports have described aberrant expression of 
E-cadherin and vimentin in normal prostate tissues (Figiel et al., 2017; Rubin et al., 2001), 
strongly indicating that further research is necessary to understand whether the EMT 
morphological features of untreated RWPE-1 cells are induced by HPV and validate the use 
of these cells as an experimental model for normal prostate epithelial cells. 
As expected, PC-3 carcinoma cells were characterized by an EMT phenotype and no 
additional morphological modifications were induced by BKPyV infection. In contrast, 
BKPyV infection increased their invasive potential. 
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Considered as a whole, our results show that a) normal epithelial prostate RWPE-1 cells and 
PC-3 cells are infectable with BKPyV, but the outcomes of infection vary, b) cell 
proliferation and TNF-α production were increased by BKPyV in RWPE-1 cells, but not in 
PC-3 cells, c) adhesion to Matrigel and invasion potential, observed as MMP-2 and MMP-9 
activities, were increased upon BKPyV infection of RWPE-1 cells, d) both mock treated and 
BKPyV-infected RWPE-1 cells exhibit loss of E-cadherin and expression of vimentin. 
In conclusion, we hypothesize that BKPyV may establish an abortive infection in normal 
epithelial prostate cells and change some phenotypic features, such as the proliferation, 
adhesion and invasive potential, but then it is not needed for maintaining the transformed 
phenotype of prostate tumor cells. However, the fact that mock treated RWPE-1 cells exhibit 
some phenotype modifications related to EMT represents a limit of this in vitro model. 
Therefore, further research is required to verify the transformation of the cells and the 
possible integration of the viral genome and thus to confirm or to deny the usefulness of these 
cells as an experimental model of normal prostate epithelial cells. 
 
. 
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Table 1: Cytokine and chemokine concentration trends in BKPyV-infected RWPE-1 and PC-
3 cells 
 
Cytokine/chemokine 
Linear trend estimation*,** 
RWPE-1 PC-3 
IL-18 R2 0.69; p=0.02 R
2 0.89; p=0.09 
TNF-α R2 0.85; p<0.01 R2 0.61; p=0.80 
MCP1 R2 0.59; p=0.04 R2 0.86; p=0.17 
IL-15 R2 0.24; p=0.26 n.a. 
IL-2 R2 0.4; p=0.12 R2 0.13; p=0.26 
IL-6 R2 0.03; p=0.71 R2 0.80; p=0.42 
IL-9 R2 0.07; p=0.55 R2 0.20; p=0.07 
GM-CSF R2 0.3; p=0.1 R2 0.39; p=0.4 
FGF-basic R2 0.21; p=0.29 R2 0.99; p=0.12 
MIP-1a R2 0.26; p=0.24 R2 0.59; p=0.06 
MIP-1b R2 0.04; p=0.95 R2 0.01; p=0.60 
IL-3 R2 0.56; p=0.05 R
2 0.96; p=0.36 
M-CSF R2 0.03; p=0.70 R2 0.74; p=0.66 
SDF-1 R2 0.29; p=0.20 R2 0.89; p=0.64 
*compared to uninfected RWPE-1 cells 
**from 1 to 21 days p.i. 
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Figure captions 
Figure 1: Titration of BKPyV load, expressed as copies/mL, in RWPE-1 and PC-3 culture 
media and cell pellets, at every analyzed time points, from day 3 to day 21 p.i..  
 
Figure 2: Effect of BKPyV infection on the growth rate of RWPE-1 and PC-3 cells measured 
by the MTT assay. Data are expressed as percentage of the cell viability, compared to the 
uninfected cells (100%). 
 
Figure 3: Concentration of four most significant cytokines (A: IL-18; B: TNF-α; C: MCP1; 
and D: IL-3), measured in the culture medium of the infected and uninfected RWPE-1 cells, 
at every analyzed time points, from day 1 to day 21 p.i. Data are expressed as pg/mL and as 
percentage of increase. Linear trend estimation is indicated for every cytokines. 
 
Figure 4: Panel A and B represent the percentage of adhesion rate to the extracellular matrix 
of the BKPyV infected RWPE-1 and PC-3, respectively, at different time points, from 4 to 21 
days p.i.. Adhesion capacity is depicted as percentage of cell adhesion/square millimeter 
(mean± SD), compared to uninfected cells (100%).  
 
Figure 5: a) Representative micrographs at the fluorescence microscope showing the 
expression epithelial and mesenchymal markers in control and BKPyV-infected RWPE-1 
cells 7 days p.i. (original magnification 60x). b) Representative micrographs at the 
fluorescence microscope showing the expression epithelial and mesenchymal markers in 
control and BKPyV-infected PC-3 cells 21 days p.i.  (original magnification 60x). 
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Figure 6: A) Representative gelatin zymogram and bar graphs showing MMP-2 (B) and 
MMP-9 (C) activity in supernatants of cultured control and BKPyV-infected RWPE-1 cells. 
Data are expressed as mean ± SD. Representative gelatin zymogram and bar graphs showing 
MMP-/TIMP-2 (D) ratio and MMP-9/TIMP-2 ratio (E) activity in supernatants of cultured 
control and BKPyV-infected PC3 cells. Data are expressed as mean ± SD. 
 
Figure 7: A) Transmission electron micrographs of RWPE-1 non infected (a) and BKPyV-
infected-RWPE-1 (b) cells at 3 days showing a similar morphology. Scale bars = 0,5 µm. 
Boxed areas show at higher magnification the viral particles present in both experimental 
conditions. Scale bars = 200 nm. B) Transmission electron micrographs of RWPE-1 non 
infected (c) and BKPyV-infected-RWPE-1 (d) cells at 10 days p.i. containing viral particles 
(some indicated by white arrows). Scale bars = 0,5 µm. A viral particle from each 
experimental condition is shown at higher magnification in boxed areas. Scale bars = 120 nm. 
 
 
